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Since 1987, the federal government and state governments, have tried to combat 
counterfeit drugs from entering the United States and the states' pharmaceutical supply 
chain. The latest attempt to prevent counterfeit drugs from entering the state drug supply 
chain was the California E-Pedigree drug tracing program that was to be implemented by the 
end of 2017. The California E-Pedigree system uses GS1 PDMS tracing system as its 
guideline. Since all of the states use paper format pedigree systems, California would have 
been the first electronic pedigree system in the U.S.  
However, on November 27, 2013, the President of the United States signed into law 
the Drug Quality Security Act (DQSA). Title II of DQSA is called the Drug Supply Chain 
Security Act (DSCSA) and it removes all existing or future drug track or trace systems 
including pedigree systems from all states. DSCSA does establish a new federal drug tracing 
program that uses pedigrees and product identifiers for verification of the drugs being 
accepted by the buyer. Although the full implementation of the DSCSA will take about ten 
years from its enactment, the basic structure of the new federal tracing program is laid out.  
My thesis will analyze the current state of the pharmaceutical industry, the impact of 
counterfeit medicine, and anti-counterfeit technologies. We will proceed to analyze the 
DSCSA to create a basic logical model and show a possible implementation of its 
verification process. Additionally, we will discuss DSCSA model as to its effectiveness of the 
basic design against the entrance of counterfeit medicine into the United States 
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This thesis is an analysis and prospective implementation of the current federal 
tracing drug program, Title II of the Drug Quality and Security Act (DQSA) which is 
referred to as Drug Supply Chain Security Act (DSCSA), that was passed by Congress and 
signed into law by the president on November 27, 2013. DSCSA was created to consolidate 
the many current state drug tracing programs and future efforts to reduce counterfeit 
medicine from entering the United States pharmaceutical supply chain (USPSC). To 
understand the need for such a program, we need to appreciate the current state of the 
pharmaceutical industry, the impact from counterfeit medicine, and the anti-counterfeit 
technologies being employed. 
We analyze the pharmaceutical industry's revenues and cost, define the term 
"counterfeit medicine," and show the cost of the counterfeit medicine on the pharmaceutical 
industry, governments, and citizens. We conduct a high level review of anti-counterfeit 
technologies which ends with the new federal tracing program, DSCSA. We analyze the new 
law and come up with a basic logical model of the new trace program by providing logical 
flow charts, ERD diagrams, and product identifier verification implementation. We discuss 
the effectiveness of the new drug tracing program against known counterfeit drug intrusions 
and come to a conclusion.  
Why is the subject important? Drug counterfeiting reduces the global pharmaceutical 
industry’s revenues (Davison, 2011; World Health Organization, 2008), which in turn has an 
effect on new drug development in terms of costs and productivity (Davison, 2011). In 
addition, counterfeit drugs have human, corporate, and governmental costs (Davison, 2011). 





medical co-payments, insurance rates, and taxes. These detrimental effects are not only 
found in undeveloped nations but are found in an alarming rate in developed nations (J. 
Morris & Stevens, 2006; Wertheimer & Wang, 2012). In addition, organized crime is 
involved at all levels of drug counterfeiting (Davison, 2011; UNICRI, 2013; Wertheimer & 
Wang, 2012). 
First we analyze the global pharmaceutical industry’s (GPI) revenues and costs and 
then follow with an analysis of the United States pharmaceutical industry’s revenues and 
costs. Next, we do a review of counterfeit drugs, definition, costs, reasons for counterfeiting, 
and the involvement of organized crime. This is followed by a quick review of the anti-
counterfeit technologies which include authentication and product track-and-tracing. We 
cover the DSCSA law which provides a basic framework for the new federal drug tracing 
system and by produce a logical model by first analyzing the DSCSA's definition, structure, 
and requirements. From this logical model, we can review the effectiveness of the new 





2. Literature Review 
This section is a literary review of the current state of the pharmaceutical industry, 
counterfeit medicine, anti-counterfeit technologies, and the challenges they create. As 
indicated from this literary review, counterfeit medicine is a large problem for the global 
pharmaceutical industry but the problem is much larger in the underdeveloped (30%-50%) 
nations than the developed (1%-3%) nations (World Health Organization, 2008). To explain 
the effects of counterfeit medicine, we look at the current global pharmaceutical industry 
revenues and costs. Next, we look at the current costs of counterfeit medicine and organized 
crime involvement in counterfeit medicine. Lastly, we search the literature to find the latest 
anti-counterfeit drug technologies.  
To understand these challenges, we need to appreciate at a high level the issues of 
GPI revenues and their costs. An additional appreciation is needed on the cost of counterfeit 
drugs. We need to recognize how counterfeit drugs are entering the global supply chain and 
the USPSC. Furthermore, we need to comprehend the current anti-counterfeit drug 
technologies. 
First, let's look at the pharmaceutical revenues because without an easy profit to be 
made by the counterfeiters, there would not be any counterfeit drugs (Davison, 2011; 
UNICRI, 2012; Wertheimer & Wang, 2012). To follow revenue, we need to cover the cost 
of producing a drug that is sold on the market and the productivity issues. We then cover the 
cost of counterfeiting and how counterfeit drugs are entering the USPSC. Lastly, the anti-
counterfeit technologies will be covered. 





2.1 Pharmaceutical Industry Revenues 
Using the International Federation of Pharmaceutical Manufacturers & Associations 
(IFPMA) report for 2011, Annex 3 data, the total global pharmaceutical sales revenues for 
2011 was calculated to be over $1,086 billion (International Federation of Pharmaceutical 
Manufacturer & Associations, 2012). IFPMA stated that in 2011 the United States had the 
largest market, with 31% percent of the global sales market (International Federation of 
Pharmaceutical Manufacturer & Associations, 2012). The next biggest market was Japan,  
followed by China, Germany, and France. (see Table 1) 
Table 1     PHARMACEUTICAL SALES (2011)
Rank GEOGRAPHY US$BN Percent of Market
1 United States 337.10$   31.02%
2 Japan 127.38$   11.72%
3 China 66.86$     6.15%
4 Germany 55.15$     5.07%
5 France 48.66$     4.48%
Source: The Pharmaceutical Industry and Global Health: Facts and Figures 2012
Retrieved: 3/15/2014  
Pharmaceutical Executive reported in 2013that the top 50 global pharmaceutical 
companies have total product revenues over $594 billion (Noor, May 1, 2013). The top five 
companies are Pfizer, Novartis, Merck & Co., Sanofi, and Roche for a total over $209 





No. Company Company HQ RX Sales (US$Bn)
1 Pfizer USA 47.404$                           
2 Novartis Switzerland 45.418$                           
3 Merck USA 41.143$                           
4 Sanofi France 38.370$                           
5 Roche Switzerland 37.542$                           
6 GlaxoSmithKline UK 33.107$                           
7 AstraZeneca UK 27.064$                           
8 Johnson & Johnson USA 23.491$                           
9 Abbott USA 23.119$                           
10 Eli Lilly USA 18.509$                           
Total 335.167$                        
Source: The 2013 Pharm Exec Top 50
Retrieved: 6/10/2014
Table 2     2013 PharmExec Top Ten
 
My further investigation of the data and calculations reveals seventeen companies 
out of the top 50 are United States companies that have aggregate sales revenues over $232 
billion. Switzerland had three companies with an aggregate sales revenues over $87 billion 
making it number two on the list. Japan had 10 companies with aggregate sales revenues 
over $68 billion. United Kingdom follows with aggregate sales revenue over $60 billion. 
Germany had five companies with aggregate sales revenues over $41 billion.  
According to IMS Health, global pharmaceutical revenues have been increasing for 
decades, except for a decrease from 2011 to 2012 from $964.8 to $962.1, a loss of $2.7 

















Note: US$ uses actual quarterly exchange rates
Source: IMS Health Market Prognosis, June 2013
Retrieved Date: 3/17/2014
Total World Market 
Total Unaudited and Audited Global 
Pharmaceutical Market
 
The United States pharmaceutical market reported a loss of revenue from 2011 to 
















In 2013, eight out of the top twenty global pharmaceutical firms experienced a drop 





Table 5 TOP 20 GLOBAL CORPORATIONS 2013 
2013 RANK Company 2013 SALES 2012 SALES Sale Diff.
1 NOVARTIS 50,576$      50,521$      55$              
2 PFIZER 44,330$      46,707$      (2,377)$       
3 SANOFI 38,181$      38,531$      (350)$          
4 MERCK & CO 36,350$      39,891$      (3,541)$       
5 ROCHE 36,146$      34,958$      1,188$        
6 GLAXOSMITHKLINE 32,544$      32,736$      (192)$          
7 JOHNSON & JOHNSON 30,784$      27,717$      3,067$        
8 ASTRAZENECA 30,257$      31,704$      (1,447)$       
9 TEVA 24,258$      24,762$      (504)$          
10 LILLY 23,045$      21,583$      1,462$        
11 AMGEN 18,621$      17,103$      1,518$        
12 ABBVIE 18,150$      17,881$      269$            
13 BOEHRINGER INGELHEIM 17,375$      16,889$      486$            
14 BAYER 17,276$      16,431$      845$            
15 NOVO NORDISK 14,300$      12,576$      1,724$        
16 TAKEDA 13,399$      15,909$      (2,510)$       
17 ACTAVIS 12,742$      12,375$      367$            
18 MYLAN 11,087$      10,325$      762$            
19 BRISTOL-MYERS SQB. 11,023$      12,756$      (1,733)$       
20 GILEAD SCIENCES 11,011$      9,540$        1,471$        
 491,455$   490,895$   560$            
Note: US$: Sales and Rank are in US$ with quarterly exchange rates 
Sales cover direct and indirect pharmaceutical channel wholesaler and manufacturers 
The figures above include prescription and certain over the counter data and represent 
manufacturer prices 
Source: IMS Health MIDAS, December 2013 
Retrieved: April 14, 2014
 (US$ Mn)
 
Some of the above losses can be explained by the loss of exclusivity of patented 
blockbuster drugs (sales revenue greater than US $1 billion/year). From a 2014 article by EP 
Vantage, major revenue losses reported for patent blockbuster drugs occurred in 2011, 2012, 
and 2013. In addition, the reported losses were offset by new sales for the same years (Plieth 





2011 2012 2013 2014e 2015e 2016e 2017e 2018e
Total sales at risk 32.60$    54.70$    34.30$    38.70$    47.50$    38.80$    32.60$    35.80$    
Actual sales lost or forecast 
to be lost (17.00)$  (38.20)$  (29.10)$  (24.00)$  (17.00)$  (15.60)$  (17.40)$  (15.60)$  
Sale replaced 36.00$    47.00$    26.80$    54.20$    58.40$    60.40$    62.90$    58.60$    
Net of Sale replaced - Actual 
Forecast Sales Lost 19.00$    8.80$      (2.30)$     30.20$    41.40$    44.80$    45.50$    43.00$    
Retrieved: 3/18/2014
Table 6     Global sales at risk of patent expiry (US$Bn)
Source: http://www.epvantage.com/Universal/View.aspx?type=Story&id=489880
Note: Shaded area is projected
 
The projected total patent blockbuster drug losses for the years of 2014, 2015, 2016, 
2017, and 2018 are offset by the projected sales increases for the same time period. Looking 
at the figures of projected losses and gains for 2014 to 2018, it appears the blockbuster drug 
productivity problem of the 1990s and early 21st century has abated. (see Table 6) 
2.2 Pharmaceutical Industry Cost Structure 
The pharmaceutical cost structure is very complicated. For example, some of the 
variations in the cost structure are dependent upon the phase of the drug pipeline and  a 
drug’s therapeutic class. The following figure displays how each therapeutic class has its own 





Source: R&D Costs and Returns by Therapeutic Category
Retrieved: April 11, 2014
 
Another example of different cost structure is in clinical development which on 
average takes about 7.2 years. However, clinical development is 5.2 years for AIDS antiviral 
drugs and 7.9 years for antineoplastic drugs, while neuropharmacologic and cancer drugs 
take about 9 years to transverse clinical trials (Kaitin, 2010). The longer the period of time 
that a drug spends in the clinical trials and approval phase, the higher the cost for drug 
development. (see Figure 2) 
In addition, research, development, and license costs can be from 20% to 40% of the 
overall cost structure (Gassmann, Reepmeyer, & Maximilian “von” Zedtwitz, 2004). The 
other costs in developing a drug are production (15-30%), technical and administration (5%-






Source: Deconstructing the Drug Development Process: The New Face of Innovation
Retrieved: June 25, 2014  
2.3 Pharmaceutical R&D Structure, Process, and Cost 
2.3.1 R&D Structure 
You must understand the structure and the process of pharmaceutical industry 
research and development (R&D) to see the effects it has on the costs and productivity. Cost 
and productivity affects profits. First we start with an analysis of the drug discovery and 
development process structure, which is referred to as the drug pipeline (Long & Works, 
2013). (see Figure 3) If we take a quick look at the possible cost per stage of the pipeline, we 






















Figure 3 Pharmaceutical Drug Pipeline
 
 
Source: How to improve R&D productivity: the pharmaceutical industry's grand challenge
Retrieved: March 27, 2014
 
2.3.2 R&D Process 
It may take 10-15 years before a drug is released to the market from the drug pipeline 
(Clinuity, 2009; Danzon, Nicholson, & Pereira, 2005; Long & Works, 2013; Paul et al., 2010). 
The drug pipeline is broken up into multiple development phases: drug research, preclinical, 
clinical trial phase I,  clinical trial phase II, clinical trial phase III, pre-launched, launched, 
phase IV, and suspended (Lloyd, 2014; PhRMA, 2014). The drug research phase is broken 





begins with five to ten thousand compounds which are reduced to about 250 compounds 
that will enter the preclinical phase. (Clinuity, 2009) 
Preclinical testing is where the lead compound is involved in laboratory and animal 
testing to indicate whether the compound is suitable for human testing (Long & Works, 
2013; PhRMA, Unknown; Sobel & Reisner, 2008). Researchers determine the efficacy levels, 
side effects, absorption, distribution, metabolism, elimination and duration of the lead 
compound. Included in the preclinical phase are methods that are developed to make large 
quantities of the lead compound which are of commercially viable purity (Sobel & Reisner, 
2008). Before the lead compound can enter clinical testing, the research company needs to 
file an Investigational New Drug (IND) Application with the FDA. The FDA review of the 
IND takes about 30 days (Sobel & Reisner, 2008). 
The time it takes from the start of the drug research phase to the end of preclinical 
phase is about three to six years (Paul et al., 2010). About five drugs are submitted from the 
end of the preclinical phase for an IND and, if accepted, will progress to the first clinical 
phase using human patients (Long & Works, 2013; Paul et al., 2010). During the preclinical 
phase, active compounds can be formulated into different forms which can be patented. 
(Sobel & Reisner, 2008) Thus, pharmaceutical and biotechnology patents are applied to 
formulations, compounds, nucleic acids, proteins, antibodies, research tools, methods of 
manufacture, and methods of treatment (Sobel & Reisner, 2008). 
After the drug research and preclinical phases, clinical trials are next where a 
prospective compound is tested on human volunteers. The clinical trials consist of phase I, 
phase II, and phase III. It takes about two to ten years, with an average of five years, for a 
drug to successfully pass all three phases in clinical trials (The Campbell Family Cancer 





pharmaceutical company who submitted the drug for clinical trials or its designee (NIH, 
2012). These clinical trials are highly regulated by governments according to good clinical 
practices (GCP) which include adequate human protection (HSP) (FDA, 2014a). In some 
countries, GCP have been adopted as laws and/or regulation (College, 2014). The FDA 
regulations concerning clinical trials include both GCP and HSP which have been in effect 
since the 1970s (FDA, 2014a; Vijayananthan & Nawawi, 2008). 
After the IND is accepted by the FDA, the prospective drug begins phase I of the 
clinical trials (PhRMA, 2014). The purpose of phase I of the clinical trial is to test for safety, 
tolerability, and chemical structure effects on the body (The Campbell Family Cancer 
Research Institute, Unknown). There are usually a hundred or fewer healthy volunteers for 
phase I trials (PhRMA, Unknown). After the drug has successfully completed the phase I 
trial, the phase II trial will begin using about 100 to 500 volunteers that have the disease or 
condition that the drug is supposed to treat (PhRMA, Unknown). The purpose of this trial is 
test the drug efficacy and dose response (PhRMA, Unknown; The Campbell Family Cancer 
Research Institute, Unknown). By the end of the first two trials the drug has been tested 
against humans for safety and efficacy (Sobel & Reisner, 2008; The Campbell Family Cancer 
Research Institute, Unknown). The phase III trial is a randomized test against a placebo 
using 1,000 to 5,000 patients throughout the world. The phase III trial may take multiple 
years and millions of dollars in an attempt to show the drug is statistically effective against 
the condition or disease it is supposed to treat (FDA, 2013c). The results of the phase III 
trial determine whether the drug is released to the market.  
After the clinical trials are successful, the data from the preclinical and the three 
clinical trials are collected for as part of the New Drug Application (NDA) to the Center for 





receipt of the NDA, the FDA has 60 days to review and to approve or not approve the 
NDA (FDA, 2014c). As part of the NDA, a fee is paid to CDER by the submitting 
pharmaceutical company according to the Prescription Drug User Fee Act (PDUFA). 
Because of the PDUFA, FDA (CDER) will take six months to two years to approve the 
application (DiMasi, Hansen, & Grabowski, 2003; FDA, 2014d). Once the application is 
approved by CDER, the drug can be marketed according to its label.  
Post-approval research and monitoring, also called phase IV clinical trial, is 
conducted after the release of the drug to the market. The purpose of the phase IV clinical 
trial is to continue to monitor the long term effects of the drug in terms of safety and 
efficacy and may be required as a condition to its release to the market. 
2.3.3 R&D Costs 
According to 2011 PhRMA members' data, about 15.9% of the global 
pharmaceutical industry revenues go toward research and development (R&D) expenditure 
(PhRMA, 2013). The EvaluatePharma report of 2012 has an 18.8% ratio of global R&D to 
global revenues in 2011, and as global pharmaceutical sales increased, global R&D spending 





Source: EvaluatePharma World Preview 2018: Embracing the Patent Cliff
Retrieved: June 12, 2014
 
Again, using data from 2011 PhRMA members' data, R&D expenditure steadily 
increased until 2007 when it  flattened out (PhRMA, 2013). PhRMA members' R&D cost 
reached a peak in 2010 at $50.710 billion and by 2012 the cost had dropped to $48.485 
billion (PhRMA, 2013). (see Figure 6) 
Source: PhRMA Annual Membership Survey July 2013
Retrieved: March 12, 2014
 
There are many reasons that would explain the increased R&D spending. One 





many more targets to develop New Molecular Entities (NMEs) for cures or therapy 
(Cockburn, 2004; Ruffolo, 2006). However, there is an ambiguity on the known number of 
drug targets (Overington, Al-Lazikani, & Hopkins, 2006). A literary review on drug targets 
found an article dated 1997 by Drews and Ryser, that estimated there are 483 drug targets 
(Overington et al., 2006), but in 2000 Jurgen Drews estimated that the number of drug 
targets are from 5,000 to 10,000 due to the human genome that contains about 300,000 
genes (Drews, 2000). The human genome was sequenced in 2002 which gave way to 
estimates of  about 8,000 possible drug targets, where about 5,000 targets might be targets of 
traditional drug compounds of antibodies (~2,400 targets) and by protein drugs (~800 
targets) (Imming, Sinning, & Meyer, 2006). From the studies of ligand-binding, the number 
of targets identified are 399 molecular targets from 130 protein families and another 
approximately 3,000 targets for small molecule drugs from prediction of the human genome 
(Imming et al., 2006). Tams Bartfai and Graham V. Lees state that there were roughly 250 
targets in 2001, which increased to 600 by 2005 (Bartfai & Lees, 2010). In 2006, there are 
two papers, one by Imming et al. and another by Overington et al. that gave an estimate of 
218 and 324 drug targets respectively (Imming et al., 2006; Overington et al., 2006). In 2007, 
David S. Wishart et al. reported the number of non-redundant drug targets to be 3,027 in the 
2.0 DrugBank (Wishart et al., 2008). In conclusion, the number of drug targets is unknown. 
Another reason for the increase in R&D spending is the retooling with new 
technologies and research capabilities (Cockburn, 2004). In addition, the diseases which are 
the drug targets are becoming more complex, harder to understand, and difficult to attack 
(Cockburn, 2004). In addition,  long-term drug toxicity to humans requires longer trials and 
adds to the development costs of the drug (Kaitin, 2010). Government regulations have also 





to the FD&C Act requires that a drug has to safe but it has to demonstrate efficacy against a 
placebo (Scannell, Blanckley, Boldon, & Warrington, 2012). Other reasons that drug 
development costs rise are failure in the late-phase clinical trials (Pammolli, Magazzini, & 
Riccaboni, 2011), a focus on new therapeutic targets (Pammolli et al., 2011), and the drug 
research phase has become research intensive because the drug interaction is at the 
molecular level (Cockburn, 2004; Pammolli et al., 2011). 
2.4 R&D Drug Productivity Costs 
The R&D cost per NME reported by the IFPMA was over $1.3 billion for 2012 
(International Federation of Pharmaceutical Manufacturer & Associations, 2012), and the 
Analysis Group reported in 2013 that the development cost per NME was $1.2 billion in 
2005 dollars value (Long & Works, 2013). A published report in 2010 by Steve Morgan et al. 
concluded that in spite of thirty years of research into the cost of NME, no one has reported 
a cost estimate that can be considered to be a gold standard (Morgan, Grootendorst, 
Lexchin, Cunningham, & Greyson, 2011). Thus, I will provide an estimate for the cost per 
NME. As a further note, biologicals are not included in this analysis due to inconsistent 
reporting of biologicals approved each year until 2004, when the FDA included biologicals 
in their report. 
By examining the FDA data on the number of NMEs approved per year from 1944 
to 2012, the pharmaceutical industry reached a peak in 1996 with 53 NMEs approved by the 
FDA (FDA, 2013e). Further analysis of the data and graph of the NMEs approved by the 
FDA from 1944 to 2013 provides several pieces of information. (see Figure 7) My  
calculations show the average number of NMEs from 1944 to 2013 to be 21 NME per year. 
In addition, there are several cycles in the graph, starting with 1944 to 1950 where there was 





from 1951 until 1969 and from 1969 until 1980. A large cycle occurred from 1980 until 2009 
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Figure 7    NMEs Approved 1944-2012
Source: FDA: Summary of NDA Approvals & Receipts, 1938 to the present
Retrieved: March 13, 2014
 
Using PhRMA member's data for 2013 and the FDA NME data, we examine the 
United States R&D expenditure per NME approved by the FDA for a year. Thus, we 
provide a rough estimate of R&D cost per NME per year in the United States. The analysis 
of these calculations indicates that the R&D cost per NME broke the $1 billion mark in 
2000 and continued on an upward trend until 2009, when the cost per NME started to have 
a downward trend to 2012. The highest cost to develop an NME was in 2009 at a cost of 
$3.096 billion per NME. (see Figure 8) 
Source: FDA: Summary of NDA Approvals & Receipts, 1938 to the present and PhRMA Annual Membership Survey July 2013





Pharmaceutical industry productivity or innovation is measured by the number of 
NMEs and biologicals approved by CDER per year and the cost of R&D per year. Many 
papers have stated that pharmaceutical industry productivity is decreasing due to multiple 
reasons such as mergers (Danzon & Nicholson, 2012; Demirbag, Ng, & Tatoglu, 2007; 
LaMattina, 2011), absence of easy identifiable drugs (Scannell et al., 2012), and high failure 
rates in phase I, II, and III trails (Pammolli et al., 2011). The cost of drug development is 
increasing at a rate that only the large pharmaceutical companies can afford it and may be a 
reason for pharmaceutical mergers and acquisitions or alliances (Danzon & Nicholson, 2012; 
Gassmann et al., 2004). Some estimates of the drug success ratio from clinical trials to 
market is one out of five and from the entire drug pipeline to market the estimated ratio is 
from one out of twenty-four (Paul et al., 2010) to one out of 10,000. 
Next we analyze the current data that is available to see if these accusations are true. 
We start with the 2014 Citeline Pharma R&D Annual Review report (Lloyd, 2014). The 
Citeline Pharma R&D report provides a graph that indicates the global pharmaceutical 
industry pipeline has been increasing since 2001 (5995 drugs) to 2014 (11307 drugs); the 
pipeline is1.89 times larger in 2014 as compared to 2001 (Lloyd, 2014). (see Figure 9) 
Source: Citeline Pharma R&D Annual Review 2014






Addition data from this report indicates that the number of companies that have 
active pipelines has increased from 2001 (1198) to 2014 (3107) for an overall increase of 
260% (Lloyd, 2014). (see Figure 10) 
Source: Citeline Pharma R&D Annual Review 2014
Retrieved: March 23, 2014
 
The Citeline report further stated that the drug pipeline from 2013 to 2014 had 





Source: Citeline Pharma R&D Annual Review 2014
Retrieved: March 23, 2014  
A review of the Investigational New Drug (INDs) applications received from 1986 
to 2008 data and graph (see Figure 12) provides the following information (FDA, 
Unknownb). The number of INDs received from 1987 to 1989 was flat and afterwards 
reached a peak in 1992. After 1992, the number of INDs received decreased until 1999 and 
then remained roughly flat until 2003. After 2003, the number of INDs received increased 





Note: * 2004 to 2008 included biologics
Source: FDA: CDER ORIGINAL INDs RECEIVED CALENDAR YEARS 1986 - 2008
Retrieved: March 28, 2014
 
A review of the Number of Active INDs in phase I, II, and III at the close of the 
Calendar Year data and graph (see Figure 13) provides the following information (FDA, 
Unknowna). The number of INDs active in the clinical phases decreased from 1986 to 1989. 
Afterwards, the number of active INDs in the clinical phases increased until 1998, then 
decreased during the years of 1999 and 2000. The number of INDs active in the clinical 
phases increased from 2001 to 2008, where the data ends.  
Note: * 2004 to 2008 included biologics
Source: FDA: CDER NUMBER OF ACTIVE INDs AT THE CLOSE OF THE CALENDAR  YEARS 1986 – 2008
Retrieved: March 28, 2014
 
Generally, the period from 1980 to the 1996 indicates the number of NMEs 





number of NMEs approved increased from 1980 until 1991 and then decreased after 1991 
until 1994. The period of interest is the time period from 1995 until 2000 when the number 
of NME approved hit its peak and then continued in a downward trend until 2009. This is 
referred to as the pharmaceutical industry productivity decline because the number of NMEs 
was declining and yet the cost of R&D was going up (FDA, Unknownb). (see Figures 7 and 
14) 
Source: FDA: Summary of NDA Approvals & Receipts, 1938 to the present
Retrieved: March 13, 2014
 
The productivity of the drug pipeline has a high correlation to the number of INDs 
submitted to clinical trials. Since it takes about four to five years for an IND to clear clinical 
trials and become a drug, I would expect to see a peak in IND submittal four to five years 
before the 1996 peak and we do see a peak in 1992. Furthermore, the number INDs increase 
from 1990 to 1992 and then decrease from 1993 to 2003. This correlates to the increase of 





Note: * 2004 to 2008 included biologics
Source: FDA: CDER ORIGINAL INDs RECEIVED CALENDAR YEARS 1986 - 2008
Retrieved: March 28, 2014
 
If you take the number of approved NMEs and divide them by the number of INDs 
received for the same year and then do an average of this figure for the years of 1986 to 
2008, the average drug productivity per year would be about one to two NMEs approved 
per one hundred INDs submitted from 1986 to 2008, which is a much lower than  the 1 out 
of 25 or 1 out of 5 others have quoted. 
2.5  Counterfeit Medicine 
2.5.1 Introduction 
Because disease has plagued earth for millions of years (Capasso, 2005; McLain, 
1991), medicine and their recipes have been in existence in an herbal, animal, or mineral 
form since early man to combat these diseases and other maladies (Ji, Li, & Zhang, 2009; 
Venzmer & Koenig, 1972). There is a high probability that someone has modified someone 
else's medical recipe and used it during this period. Today's equivalent would be cook books 
where old recipes have been given a new slant with new or different ingredients. Since none 
of the cook books would be regarded as the official standard cook book, the changed recipes 





A Greek physician Pedanius Dioscorides in the 1st century C.E. created a formal 
document called Materia Medica that was accepted as a standard (Ji et al., 2009; Parker, 1915). 
The Materia Medica contain about 600 plants and 1000 drugs recipes (DerMarderosian, 1996)  
and could be called the first pharmacopeia (De Vos, 2010). Materia Medica was considered the 
official medical text until the beginning of the 19th century (De Vos, 2010).  
Since the creation of the Materia Medica, several civilizations have added to this 
medical text. It was the responsibility of physicians to make medicine for their patients from 
the Materia Medica and add to the Materia Medica. It wasn't until the Islamic empire around 
8th century or 9th century C.E that apothecary shops were created (Al-Ghazal, 2003; 
Hamarneh, 1962; Syed, 2002) and inspected by a syndic (Muhtasib) in Baghdad and 
elsewhere for the sole purpose to eliminate counterfeit medical recipes (Syed, 2002). It was 
the responsibility of the apothecary to make the medicine for the physician or for a patient 
from a prescription from a physician. Since then, there have been many incidences of 
counterfeit medicine and nostrums given or prescribed to a patient. It was not until the late 
19th century that western governments started to seek control over medicine for the 
purpose of safety, efficacy, effectiveness, and correct formulary. 
One item of note that is often left out of the many reports on counterfeit drugs is 
that the cost of pharmaceutical-branded prescription drugs is in the drug’s development and 
not in its manufacturing (Davison, 2011). This is one of the many reasons the selling of 
counterfeit drugs is so lucrative. A branded prescription drug is usually patented, which 
allows the drug developer to charge a high price to reimburse the cost of the development of 





 2.5.2 Definition of Counterfeit Medicine 
One of the problems with the term "counterfeit medicine" is its definition as many 
nations and organizations cannot seem to agree on a single one (Chika, Bello, Jimoh, & 
Umar, 2011; Wertheimer & Wang, 2012). Counterfeit medicine in one nation may not be a 
counterfeit medicine in another. For example, India, which is the number one exporter of 
counterfeit drugs, never uses the word “counterfeit” but uses the term "spurious drugs” 
instead (Gautam, Utreja, & Singal, 2009). The World Health Organization (WHO) has their 
own definition (World Health Organization, 2007); the Pharmaceutical Security Institute 
definition is based upon the WHO definition (Pharmaceutical Security Institute, 2014d). The 
US Federal Food, Drug, and Cosmetic Act also defines a counterfeit drug differently than 
the WHO (World Health Organization, 2007). We will define a counterfeit drug or medicine 
for this thesis to be a drug that is deliberately and fraudulently mislabeled with respect to 
identity and/or source, tampered with, adulterated, spurious in nature, and/or just generally 
substandard. This definition applies to brand and generic drugs which include gray 
pharmaceuticals.  
The gray pharmaceutical market consists of unregulated secondary wholesalers that 
sell drugs of unknown source, quality, and efficacy. Sometimes these drugs are stolen and are 
sold at a discount price. Other times, these gray market drugs are counterfeit. The gray 
pharmaceutical market also is referred to as parallel drug trade (Finlay & Center, 2011). 
2.5.3 Cost of Counterfeit Medicines 
What is the cost of counterfeiting drugs and how prevalent is drug counterfeiting? 
WHO estimates that 10% of worldwide medicine is counterfeit (UNICRI, 2012). Nations 
that have an effective law enforcement and pharmaceutical supply chain (PSC) control 





Green, & Newton, 2008; World Health Organization, 2008). Whereas in some countries the 
percentage of counterfeit medicine can be as high as 30%, which includes several countries 
in Africa and parts of Asia and Latin America (Attaran, Bate, & Kendall, 2011; Fernandez et 
al., 2008; World Health Organization, 2008). In 2013, the Pharmaceutical Security Institute 
(PSI) reported 2,193 incidents of pharmaceutical crime that involved 317 different 
pharmaceutical products in 124 nations (Pharmaceutical Security Institute, 2014a; 
Pharmaceutical Security Institute, 2014b; Pharmaceutical Security Institute, 2014c). (see 
Figure 16) WHO estimated in 2003 that the counterfeit medicine was worth $32 billion 
(Chika et al., 2011) and with a expansion rate of 13% per year that became a $75 billion 
global business by 2010 (Attaran et al., 2011; Chika et al., 2011; Pitts, 2009; World Health 
Organization, 2007).  My own calculation is that the counterfeit medicine was a $109 billion 
business by 2013. With the GAO reporting that there were over 34,000 rogue Internet 
pharmacies (United States Government Accountability Office, 2013) and with LegitScript 
only verifying 214 online pharmacies to be legitimate (LegitScript LLC, 2013), the percentage 





Source: Pharmaceutical Security Institute: Incidents Trends
Retrieved: April 4, 2014  
Since 2010, the U.S. Immigration and Customs Enforcement (ICE)  Homeland 
Security Investigations (HSI) has participated in an operation called Apothecary. The 
purpose of Operation Apothecary is to combat the use of the Internet for illegal drug 
distributions and has so far resulted in 1,048 seizures that had MSRP value of $20 million, 
115 arrests, and 112 indictments which resulted in 99 convictions (U.S. Department of 
Homeland Security, 2014). 
In 2013, ICE reported to Congress that a worldwide collaboration of 100 nations 
was involved in an operation called Pangea VI. The purpose of this operation was the 
targeting of illicit websites for selling counterfeit medicine. The result of the operation was a 
seizure of 10 million units (tablets or capsules) of counterfeit medicines worth about $36 
million and 13,763 illicit online pharmacy web sites were shutdown (INTERPOL, 2014a; 





From 13 to 20 of May 2014, 111 countries and 196 agencies participated in Pangea 
VII. Pangea VII resulted in 9.4 million units of fake or counterfeit drugs seized that had a 
street value of $36 million. In addition, Pangea VII resulted in 239 arrests and more than 
10,600 websites shutdown (INTERPOL, 2014a). 
2.5.3.1 Human Cost 
In the U.S., the Internet is problematic for controlling counterfeit drugs. Nearly one 
out of four adults surveyed had purchased drugs online. As reported in a United States 
Government Accountability Office (GAO) report that was dated 2013, thirty-percent of 
those who purchased drugs online didn't understand how to buy drugs safely online (United 
States Government Accountability Office, 2013). In addition, the same GAO report stated 
that many of the online pharmacies were fraudulent businesses. These fraudulent online 
pharmacies are commonly known as "rogue" websites. Although the total number of rogue 
Internet pharmacies is unknown, the GAO reported that there were over 34,000 active rogue 
Internet pharmacies as of April 2013 (United States Government Accountability Office, 
2013). 
LegitScript is a privately owned company founded in 2007 whose functions are to 
actively track online pharmacies and dangerous health products, provide threat assessments 
of public and brand integrity, provide online reports about online pharmacies and health 
product, evaluate drugs and health products for safety, and provides certification for online 
pharmacies that is recognized by the National Association of Boards of Pharmacy (NABP). 
As of June 2014, LegitScript has found 37,900 active Internet pharmacies, of which 
35,839 are not legitimate. LegitScript has verified 214 online Internet pharmacies to be 
legitimate. This would indicate that more than 94.6% of the online pharmacy websites are 





websites are fraudulent, they are also in violation of several state and federal laws by selling 
unapproved, counterfeit, or out-of-date drugs and controlled substances to locations in the 
United States.  
One example of buying counterfeit drugs online occurred in 2010 during the H1N1 
flu scare when generic Tamiflu was being sold on the Internet (Green, Nettey, & Wirtz, 
2008; Mackey & Liang, 2011). Authorities purchased generic Tamiflu without a prescription 
from a legitimate looking website which was an illegal online pharmacy. An examination of 
the drug obtained had found no API. The drug contained an antibiotic similar to penicillin 
which would have been harmful or life-threatening to anyone allergic to penicillin (FDA, 
2013f). 
Another example occurred in 2008 in Singapore. In the first five months of the year, 
150 people who reported being sick were found to have severe hypoglycemia, a sudden 
decrease of blood sugar levels. Four out of the 150 people died and seven suffered severe 
brain damage (Kao et al., 2009; World Health Organization, 2010). This was caused by a 
counterfeit erectile dysfunction drug that contained large doses of glyburide, which is used to 
treat diabetes (Kao et al., 2009). 
As reported by a PLoS Medicine article dated 2008, an investigation into an. anti-
malaria drug was conducted by INTERPOL and Western Pacific World Organization 
Regional Office. The two agencies took samples of genuine and counterfeit artesunate from 
the nations of Vietnam (75), Cambodia (48), Lao PDR (115), Myanmar (Burma) (137), and at 
the Thai/Myanmar border (16) (Newton et al., 2008). The samples believed to be counterfeit 
(195/391) were found to contain no active product ingredient or too little to be effective. In 
addition, the report claimed there was a large amount of counterfeit artesunate drug on the 





confidence in the artesunate drug, and caused large economic losses for legitimate 
manufacturers. The PLoS Medicine report made a further claim that malaria might become 
drug resistant due to the artesunate drugs because of the low dosage of artesunate in the 
counterfeit drugs (Newton et al., 2008). 
The worldwide death totals due to counterfeit drugs is unknown, as is the scale of 
the counterfeit business. What we do know is that there is a human cost, such as the several 
hundred people who died over a single incident of counterfeit drug due to its toxicity. 
Furthermore, you need to include the tens of thousands of people that did not die but may 
have been made very sick or prolonged their sickness from counterfeit (substandard) drugs. 
Counterfeit (substandard) drugs can create drug resistance infections, increase hospital stay, 
additional doses of the drug be required. In addition, new drugs will have to be developed to 
replace the ineffective drug, which will increase costs to the patient and health care system. 
Due to counterfeit dugs, the consumer may pay more for their drugs because 
pharmaceuticals companies have to pay for higher insurance rates, damage claims, and loss 
of revenues (JDS Uniphase Corporation, 2013). 
To give some additional numbers to the human cost: 
 Counterfeit tuberculosis and malaria drugs kills 700,000 people a year 
(Attaran et al., 2011; UNICRI, 2013); 
 Counterfeit vaccine for meningitis caused 60,000 people in Nigeria to suffer 
with 2,500 to 3,000 killed in 1995 (J. Morris & Stevens, 2006; Paradise, 1999). 
2.5.3.2  Corporate Cost 
By looking at the PSC, we see the number of businesses that would lose revenues 































Figure 17     Traditional Pharmaceutical Supply Chain
Wholesaler 2
 
There is a corporate cost in combating counterfeit medicine whether it's in the pill 
size, shape, color, packaging, and labeling. In addition, there is the cost of recall that the 
manufacturer is burdened with when the counterfeit drug is discovered. Counterfeit drugs 
also  increase the cost of insurance for liability (Davison, 2011). 
Once a brand drug is discovered as being counterfeit, brand erosion begins 
immediately, as was the case with Tylenol (Davison, 2011; JDS Uniphase Corporation, 2013; 
Kaplan, 1998). The Tylenol adulteration in 1982 killed seven people in the Chicago area and 





retail value of $100 million (Kaplan, 1998). In addition, the J&J brand’s longstanding 
reputation of trustworthiness fell as its common stock dropped in value by $2.31 billion 
(Dowdell, Govindaraj, & Jain, 1992). Furthermore, J&J experienced brand erosion of 
Tylenol and saw its market share drop from 37% to 7%. However, Tylenol did recover its 
leading market position after the product package was redesigned and with a heavy price 
promotion (Kaplan, 1998).  
Brand drug owners have never faced any litigation for damages due to counterfeit 
versions of their drug. Thus, the actions taken by the brand owner to identify the offending 
drug, to determine whether it is counterfeit or not, to inform the public about the 
counterfeit drug, and to remove the brand drug from the market are steps taken to preserve 
their own image and the brand’s image. This was the case of the Tylenol adulterations 
2.5.3.3  Government Costs 
Counterfeit drugs can cause the loss of public support in the healthcare system and 
government (Davison, 2011; JDS Uniphase Corporation, 2013). In severe cases of 
counterfeit drugs, politicians and regulators are also blamed for their lack of supervision of 
the healthcare system (JDS Uniphase Corporation, 2013). Counterfeit drugs can also increase 
government healthcare costs through increased spending on nurses, doctors, hospital time, 
and proper drugs to cure the patient (Davison, 2011; JDS Uniphase Corporation, 2013)and 
destroy a government image which might impact its international trade (Davison, 2011). 
Because of counterfeit drugs, there is an increased burden on the family, friends, and 
patients due to the increase financial cost of co-pays, insurance rates, and taxes (Davison, 
2011). With the increasing threat of counterfeit drugs, governments are seeing an increase in 
the cost of labor because of hiring more regulatory personnel to oversee the pharmaceutical 





2013; Yankus, 2007). For example, the U.S. FDA has offices in China, India, Costa Rica, 
Mexico, Chile, and Jordan for the purpose of overseeing the food and drugs exported to the 
United States. 
2.5.3.4 Organized Crime 
The United Nations Convention against Transnational Organized Crime (UNTOC) 
(2000) defines organized crime as a 
structured group of three or more persons, existing for a period of time and acting in 
concert with the aim of committing one or more serious crimes of offences...in order 
to obtain, directly or indirectly, an economic or other material benefit (UNICRI    , 
Organized Crime Strategies in the Production and Trade of Counterfeit Medicine,  p. 
24).  
This definition includes the Chinese triads, Colombian cocaine traffickers, Mexican 
Mafia, Russian Mafia, Hezbollah, and al Qaeda, which are all involved in the making and 
selling of counterfeit drugs (Bate, 2008; Finlay & Center, 2011; Mackey & Liang, 2011; 
Partnership for Safe Medicines, 2014).  
Counterfeit medicine is a high profit and low risk enterprise for organized crime. 
High profits are obtained for the following reasons:  
 The equipment that is used for illicit drugs can be used for counterfeit drugs 
(UNICRI, 2013). 
 Trade routes have already been established with the illicit drugs, which means 
organized crime can use the same means of corruption, intimidation, and extortion 
practices and includes the same methods of concealment and document forgery 





 The same alliances used in the illicit drug trade are used in the counterfeit drug trade 
(UNICRI, 2013). 
 High demand for the counterfeit drugs by those who can't afford the drugs in the 
current market and for those persons seeking a counterfeit version of the drugs (JDS 
Uniphase Corporation, 2013; UNICRI, 2013; Wertheimer & Wang, 2012). 
 New or used tablet machines that are used to produce the legitimate drug can be 
easily bought and used to produce counterfeit drugs (UNICRI, 2013). 
 Cost of production is low and the selling price is very high (Davison, 2011; UNICRI, 
2013). 
 Cost of the contaminant is very cheap as compared to the API (Bate, 2008; Davison, 
2011). 
The reasons for low risk are the following: 
 Little or no enforcement and penal sanctions (Davison, 2011; JDS Uniphase 
Corporation, 2013; World Health Organization, 2007) 
 Little or no political will and commitment (Wertheimer & Wang, 2012; World Health 
Organization, 2007) 
 Insufficient or appropriate drug legislation (World Health Organization, 2007) 
 Missing or weak drug legislation (Wertheimer & Wang, 2012; World Health 
Organization, 2007) 
 Bribery and conflict of interest (Bate, 2008; Wertheimer & Wang, 2012; World 
Health Organization, 2007) 
 Complex pharmaceutical supply chain (Bate, 2008; Wertheimer & Wang, 2012; 





 Pharmaceutical medicines not regulated by the exporting country and within free 
trade zones (Wertheimer & Wang, 2012; World Health Organization, 2007) 
2.5.3.5 How are Counterfeit Drugs Entering the Pharmaceutical Supply Chain?  
The PSC is a very complicated logistic system. In the United States there are three 
basic models of PSC: the traditional wholesaler,  the limited distribution model, and  the 
direct distribution model. (see Figure 17)  All three models start with the pharmaceutical 
manufacturer, who uses the API (raw material) to create drugs in their many forms. We start 
with the manufacturers and their API manufacturers to demonstrate how counterfeit drugs 
can enter the PSC from the API manufacturer. (See Figure 18) 
Drug Manufacturer











































Figure 18     Pharmaceutical Supply Chain - Point of Vulnerability
 
The FDA reported in June 2011 that 80% of the pharmaceutical API and 40% of 





pharmaceutical API being made outside the U.S., it is easier for counterfeit API to enter the 
USPSC and ultimately make their way to the consumer. To prevent counterfeit API from 
entering the United States, the FDA performs inspections of the manufacturing API plants 
and the API is routinely tested by the drug manufacturers in the United States and abroad 
(Health Group, 2011; Usdin, 2009). Often, API testing technology is based upon 1950s 
technology that was established for off-patent drugs by the U.S. Pharmacopeial Convention 
(USP) (Health Group, 2011; Usdin, 2009). Another problem with oversea manufacturing 
API plants is the failure by the FDA to perform pre-inspection and timely inspections of 
these plants before allowing U.S. drug manufacturers to buy API from them (Harris, 2008; 
Usdin, 2009). The failure of the FDA to do a pre-approval inspection of the manufacturing 
API plant before giving their approval and the failure of the USP test to detect the 
contaminant in the API was the situation in the counterfeit heparin case. 
Heparin is an anticoagulant drug that has been used since the 1930s (Briones, 2008). 
The majority of the world supply of heparin API is made in China and Baxter International   
Inc. was a major importer of the heparin API into the United States (Mintz & Liu, 2013) 
when suspicion about contaminated heparin manufactured by Baxter surfaced in Missouri 
around November 2007. By January 2008, some 50 reports of allergic reaction in six states 
came to the attention of the Center for Disease Control and Prevention (CDC). The FDA 
and Baxter had determined by the second week of January that the adverse reports were 
linked to nine lots of multi-dose heparin vials. On January 17, 2008 Baxter recalled the nine 
lots that appeared to be contaminated (Mintz & Liu, 2013; Usdin, 2009). 
By the first of February, the CDC had reported 65 confirmed or probable cases of 
allergic reactions to Baxter heparin which indicated the earlier recall of the nine lots of 





heparin were not contaminated, a full recall of the remaining lots manufactured by Baxter 
was conducted on February 28, 2008. By March 2009, the FDA had received notices of 21 
deaths and 785 adverse reactions to the contaminated heparin (Usdin, 2009). 
The FDA discovered that twelve Chinese companies supplied the contaminated 
heparin to eleven countries (Kishimoto et al., 2008; Mintz & Liu, 2013; Usdin, 2009). PEW 
reported in 2011 that there were 178 deaths and 880 adverse reactions to the counterfeit 
drug from January 2007 to September 2008 (Health Group, 2011). (see Figure 19) 
Source: After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs
Retrieved: June 27, 2014
 
The FDA tested the suspicious heparin according to approved methods, which were 
established by the USP in the 1950s, and all samples passed the tests for contaminates 
(Health Group, 2011; Usdin, 2009). This created the need to find another test(s) that would 
identify the contaminates in the heparin API. The FDA posted two new methods for testing 
the heparin API on March 6, 2008: capillary electrophoresis (CE) and nuclear magnetic 
resonance (NMR) spectroscopy (Usdin, 2009).  
A task force was created to do the investigation with the FDA into the heparin 
contamination. On March 17, 2008, the FDA and the task force both agreed that over-





2011; Kishimoto et al., 2008; Usdin, 2009). The new tests were followed by animal tests that 
verified the contaminant was responsible for the allergic effects displayed by the patients. 
Although the testing of contaminated heparin API was performed before manufacturing 
heparin, OSCS contaminate, a synthetic chemical, reacts similar to heparin and is why the 
previous test turned up negative for contaminates.  
The contaminated supply of heparin in the U.S. only came from Baxter. Baxter’s 
supplier of the heparin API was a company called Scientific Protein Laboratories LLC (SPL), 
which is a Wisconsin manufacturer of pancreatic enzymes and heparin. About half of the 
SPL heparin API was made by U.S. sources and the other half of the heparin API came 
from Scientific Protein Laboratories-Changzhou (SPL-CZ) in a joint venture with Techpool 
Bio-Pharma Co. Ltd. in China that began in 1999. The heparin API that came from 
Changzhou was tested and it was discovered that 20 out of the 24 samples were found to 
have an unidentified contaminant present (Usdin, 2009). 
In 2004, Baxter began to buy the heparin API from SPL-CZ but failed to inspect the 
plant until 2007 because Baxter had relied upon earlier inspection results by a different 
company. In addition, the FDA had given Baxter permission to buy the heparin API from 
SPL-CZ because it had mistaken SPL-CZ for another company in its database. It was not 
until 2008 before the FDA realized its mistake and inspected the SPL-CZ plant. The FDA 
inspections of SPL-CZ found numerous problems including not having good manufacturing 
practices. As pointed out by the Germans who found contaminate heparin in PSC which did 
not come from SPL-CZ, the problem seems to be with the upstream Chinese suppliers who 
were consolidators and their sources, the raw material workshops.  
In 2008, the FDA and Baxter both tried to inspect the consolidators and their raw 





Chinese officials have denied the contamination ever occurred. The FDA inspection on 
SPL-CZ reported that it had accepted material from unacceptable vendors and failed to 
identify contaminates in its heparin API supply which were found in more than half the 
heparin API lots. 
The question is whether the heparin contamination was a problem of poor 
manufacturing practices or a deliberate act. Chondroitin sulfate (CS) is made from animal 
cartilage and OSCS is a modified form of CS;  it mimics heparin which is made from pig 
intestines that are cooked, dried, and processed into heparin API. Since the source for 
heparin API and OSCS is different, it is viewed that the contamination of heparin API by 
OSCS was a deliberate act. In addition, OSCS is 99% cheaper than heparin API. The FDA 
viewed the OSCS contamination of the heparin API as a deliberate act because it took a level 
of sophistication and knowledge that OSCS would not show up on the routine test 
performed on the heparin API (Usdin, 2009). 
Pharmaceutical manufacturers have been known to introduce counterfeit drugs into 
the PSC whether by using non-FDA approved overseas brokers or hiding the fact they were 
using undisclosed manufacturing sites. For example, in the late 1980s and early 1990s, 
Flavine International Inc. (US) company bought drugs from non-FDA approved Chinese 
plants (Department of Justice, 1997; PEW Trusts, 2014). In the 1990s an Italian 
pharmaceutical company, Biochimica Opos, a solely-owned subsidiary of the French drug 
company Roussel-Uclaf at that time, had undisclosed and unauthorized FDA manufacturing 
sites in Italy, France, and Romania producing antibiotic drugs for them (PEW Trusts, 2014). 
Biochimica Opos falsified records to hide where these drugs were being produced. In 2001, 





felony charges for defrauding the FDA and paid a fine of $33 million (PEW Trusts, 2014; 
Reuters, 2014). 
Another manufacturer, Ranbaxy Laboratory, had been supplying generic drugs to the 
U.S. for several years and had filled 52 million prescriptions in 2007 (PEW Trusts, 2014) 
when several safety and quality issues arose in 2008 after an inspection by the FDA of the 
Poanta Sahib and Dewas plants in India(FDA, 2013a). Ranbaxy Laboratory had used non-
FDA approved manufacturing sites in obtaining their bulk API which resulted in the 
suspension of 30 Ranbaxy products from importation into the United States (FDA, 2013a; 
PEW Trusts, 2014). In 2013, Ranbaxy pleaded guilty and was fined $500 million for three 
felony FDCA counts and four felony counts of providing false statements to the FDA in 
regards to their Paonta Sahib and Dewas plants in India (Brennan, 2013; Department of 
Justice, 2013). In addition, Ranbaxy admitted to manufacturing and releasing adulterated 
drugs from their Paonta Sahib plant in 2005 and 2006 (Brennan, 2013; Department of 
Justice, 2013). A suspension was again applied in 2014 to Ranbaxy’s Laboratory Toansa plant 
in India and Ohm Laboratories plant in New Jersey which prohibited the plants from 
manufacturing and distributing APIs for FDA regulated drugs (FDA, 2014b).  
The secondary wholesale distributors (non-ADR) are the biggest offenders of 
introducing counterfeit, diverted, and stolen drugs into the USPSC. We will not focus solely 
on the U.S. secondary wholesale distributors but worldwide secondary wholesale distributors 
as well. The following are examples of secondary wholesale distributors getting caught in the 
selling and distribution of counterfeit, diverted, and stolen drugs.  
The first example of a corrupt secondary wholesale distributor has eleven individuals 
and three businesses involved in $42 million worth of counterfeit Lipitor in 2005 (NABP, 





by a distributor. The counterfeit Lipitor and some misbranded Lipitor was smuggled into the 
U.S. from South America (NABP, 2013). 
The next example is the drug Avastin which was counterfeited overseas and brought 
into the USPSC through secondary wholesale distributors. Avastin is a biologic that treats 
cancer. Since it is a biologic, a physician will order Avastin from a specialty wholesale 









Figure 20     Biological Drug Distribution
 
Counterfeit Avastin was found in a warehouse in Syria in 2009 (Blair, 2012; Faucon 
& Whalen, 2012) and in Shanghai in 2010 (Faucon & Whalen, 2012). In early 2012, a batch 
of counterfeit Avastin that contained zero API and consisted of starch, salt, a cleaning 
solvent, and other chemicals reached the United States (Weaver & Whalen, 2012). The 
supply route for the counterfeit Avastin may have begun in China and next to Egypt, then 
onto a wholesale distributor in Switzerland where the paper trial begins (Faucon & Whalen, 
2012). Then we can follow it to wholesale distributors in Denmark, Great Britain, Canada, 
and the United States (Montana, Tennessee) (Faucon & Whalen, 2012; Weaver & Whalen, 
2012). The counterfeit Avastin ended up in Los Angeles, CA at a physician's office (Blair, 
2012). The batch numbers were B6010, B6011, and B86017 and labeled as being 





A second batch of counterfeit Avastin was found that was part of the first reported 
counterfeit in February 3, 2012 (FDA, 2012a). This time the drug name on the container was 
Altuzan which is the Turkish version of Avastin (RX-360, 2014). The batch number was 
B6021 (FDA, 2012a). This batch came from Richards Pharma, aka Richards Services, 
Warwick Healthcare Solutions, or Ban Dune Marketing Inc. (FDA, 2012a).  
A third batch of counterfeit Avastin (Altuzan) was found in the U.S. in 2013 and was 
distributed by Medical Device King, aka Pharmalogical, and Taranis Medical. The batch 
numbers were B6022B01 with an expiration date of November 2013 and B6024B01 with an 
expiration date of February 2013 (FDA, 2013b). This was the first time a U.S. drug 
distributor had been implicated in the distribution of counterfeit drugs. 
The examples of the counterfeit Avastin and Lipitor had to do with obtaining drugs 
from outside of the U.S. for a cheaper price and very corrupt wholesale distributors. 
Although the Swiss, Danish, and British wholesale distributor companies were involved, all 
signs point to organized crime as being behind these counterfeit drugs. 
Although the next examples do not involve counterfeit drugs, they do involve 
corrupt wholesale distributors along with stolen and then diverted drugs worth over $1 
billion (NABP, 2013). The first case began in July of 2012 when 48 individuals had federal 
criminal charges filed against them for the diversion of drugs for Medicaid patients. The 
drugs were sold back to the pharmacies through corrupt wholesale distributors which 
resulted in the fraudulent Medicaid reimbursement payments of over $500 million (NABP, 
2013). The FDA Office of Criminal Investigation was involved in the second case, where 
twenty-three individuals and three corporations were involved in a diversion scheme that 
crossed several states and totaled more than $600 million. This second case covers the years 





chain and independent pharmacies all over the country (NABP, 2013). The pharmacies that 
received the diverted drugs had no idea of their origin and quality because the false pedigrees 
made it virtually impossible to trace.  
The repackager’s role in the PSC is to take a large number of items per container and 
break them down to a smaller number of items per container and sell them back to the 
wholesale distributor or to the dispensers (UNICRI, 2013). Repackagers can be importers of 
drugs from outside as well as inside the United States (United Nations Office on Drugs, 
2010). (see Figure 21) Repackaging is another source of counterfeit drugs being introduced 
into the USPSC. Importers can import counterfeit drugs and repackage them into legitimate 
packages and to enter them into the USPSC (Davison, 2011). Repackagers could be 
legitimate pharmaceutical companies during the day and counterfeiters at night (United 
Nations Office on Drugs, 2010). This technique is used for the more difficult drugs to 
counterfeit such as biologics (United Nations Office on Drugs, 2010) and for the 
adulteration of boxes (UNICRI, 2013). The adulteration of boxes is linked to incorrect 
dosage and expiration dates (UNICRI, 2013).  
In 2006, there were 26 incidents of counterfeit biologics in the world as reported by 
PSI (Finlay & Center, 2011). Because biologics are administered via injections or 
intravenously, counterfeit biologics are often repackaged into legitimate containers with legal 



















Figure 21     Repackager in the Pharmaceutical Supply Chain
 
For example, in 2003 three individuals were apprehended for the illicit sale and 
distribution of counterfeit Procrit,   a prescription biological drug of Amgen which is 
administered via injection (Finlay & Center, 2011). In 2006, counterfeit Fluarix, an influenza 
vaccine, was found circulating throughout Brazil by Brazilian authorities (Finlay & Center, 
2011). In 2009, immunoglobulin vials that were imported from China and repackaged under 
a leading brand name were seized as being counterfeit. In 2013, an importer was sentenced 
to two years in federal prison for buying an assortment of drugs from Turkey, India, and 
Pakistan from unapproved FDA sites, shipping them to California, repackaging the drugs, 
and then shipping them to doctors in California, Florida, Texas, and elsewhere for more 
than $7 million (NABP, 2014b). 
Another way for counterfeit drugs to enter the PSC is from unscrupulous 
pharmacists, physicians, nurses, and other medical personnel. For example, a pharmacist 
who was an owner of two pharmacies diluted some 98,000 prescriptions from 400 doctors 
from November 2000 to May 2001 in Kansas City, MO (Belluck, 2001; Elliot, 2002). A 
nurse injected AIDS patients with tap water instead of the Schedule II narcotics to satisfy 
her drug habit (Inciardi, Surratt, Kurtz, & Burke, 2006). There have also been several 





were bought from patients, repackaged, and then sold back to the corrupt or unsuspecting 
pharmaceutical wholesalers (NABP, 2014a; NABP, 2014c; Vivian, 2013). These drugs could 
have been expired or contaminated. Drug diversion in 2012 cost the New York Medicaid 
program $500 million and put Medicaid patients in risk (NABP, 2013).  
2.6 Anti-Counterfeit Technologies 
Anti-Counterfeit Technologies (ACTs) are one of many methods to combat 
counterfeit drugs from entering the PSC. There are other methods such as legal actions 
against the perpetrators, consumer education and information, private investigations, and 
cooperation between law enforcement agencies (Bansal, Malla, Gudala, & Tiwari, 2013). 
Many, if not all, of these methods have been implemented to different degrees of success. 
ACTs are constantly changing as new counterfeit methods are discovered and understood. 
ACTs are broken down into two methods: product authentication and product track-trace 
(Davison, 2011). 
2.6.1 Product Authentication 
Drug manufacturing is more than the drug composition as it entails drug label, 
container, pill or tablet size, shape, color, package, lot number, and expiration date (Davison, 
2011). All of these are copied in an attempt to introduce the counterfeit drug into the PSC. 
To combat copying the features of the drug, techniques like those used in paper money are 
used to make it difficult to copy these features of a manufactured drug. So, like paper 
money, there are many ways to authenticate the drug.  
Authenticate technologies (ATs) are broken down into two groups: digital and 
physical (Davison, 2011). Once the person is educated on what to look for, a physical 





& Wang, 2012). Digital authentication is the assignment of digital data to the container(s) 
which can be processed by a computer. Both of these ATs contain overt and covert 
technologies. 
Making tablets or pills harder to copy is like making paper money harder to 
counterfeit. This means a pill or tablet should be a unique size, shape, color, and granularity 
and adding embossing, debossing, printing, and surface marking (Davison, 2011; Power, 
Unknown). Once you understand what physical traits (on-dose features) have been applied, 
then it's easy to physically authenticate the drug. However, organized crime could copy most 
of these features which would defeat their use. In addition, once the tablet or pill is in the 
bottle there is very unlikely chance there will be random sampling during transport to 
validate the drug. This would leave it to the pharmacist to validate the drug at the pharmacy 
when the pills or tablets are removed from the transport bottle to the prescription bottle.. 
By inserting an inert substance(s) into the API, the API or drug compound will be 
harder to counterfeit. The FDA has a list of Inactive Ingredients Guide (IIG) and "generally 
recognized as safe" (GRAS) additives (Davison, 2011; Wertheimer & Wang, 2012). If used in 
combination, they can make unique markers in the drug compound or API, making it harder 
to counterfeit the API or drug compound. However, this would require special equipment to 
detect the markers in the drug. Once the pill or tablet is in the transport container to the 
wholesaler, it is highly unlikely the transport bottles will be sampled or scanned. Once again, 
the final determination of the drug authentication would belong to the pharmacist 
There are tests used to verify drugs. There are destructive and nondestructive tests 
(Davison, 2011). Destructive test means a sample has to be removed from its package and 
prepared in way as to make the sample unable to be returned to its state before testing. 





chemical and physical tests are colorimetry, hardness and dissolution, thin layer 
chromatography (TLC), ultraviolet and visible spectroscopy (Davison, 2011; Wertheimer & 
Wang, 2012). The laboratory tests are atomic absorption spectrophotometry (AAS), X-ray 
techniques, nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), gas 
chromatography (GC), liquid chromatography (LC), capillary electrophoresis (CE), and 
forensic palynology (Davison, 2011; Wertheimer & Wang, 2012). Since many of these 
techniques make the package or samples taken unsalable, these techniques are used for 
secondary analysis. Nondestructive techniques have been developed for field testing and to 
be used as primary means of testing. The nondestructive methods are portable X-ray 
diffraction, infrared spectroscopy, and terahertz imaging (Davison, 2011; Wertheimer & 
Wang, 2012).  
As we know from the Tylenol incident, primary container security can be the key to 
reducing counterfeit drugs from entering a market. Since the Tylenol incident, several OTC 
drugs have been fitted with tamper resistance seals in an attempt to indicate to the consumer 
whether the drug has been modified which allows the consumer to report the tampering 
(Shah, Prajapati, & Agrawal, 2010). There are many other primary package security methods 
that can be applied, including package design, printing, labels, holograms, and diffractive 
optically variable image devices (DOVIDs) (Davison, 2011; Shah et al., 2010). Furthermore, 
there are specialty inks, covert taggants, and forensic markers (Wertheimer & Wang, 2012). 
One or more of these techniques are usually applied to the drug container. 
2.6.2 Product Track-Trace 
We all know about product tracking from our ordering of goods on the Internet and 





company or the ordering company and track our package to find its location and delivery 
time. So, how are these products tracked? 
Products are tracked through a serial or identification number which is read, inserted, 
and updated into a computer system containing a database. The act of logging into the seller 
or shipping company computer system allows us to access the location of product through 
the serial or identification number. International Standard Serial Number (ISSN) is another 
one standard for serial numbers given to print and electronic media such as journals, 
newspaper, magazine, etc. (ISSN, Unknown). Stock keeping unit (SKU) is another standard 
serial number.  
One of the earliest adoptions of linear barcodes was for tracking library products. 
Used in large public and academic libraries, linear barcodes were cheap to print and easy to 
read for tracking books to ensure proper turnaround (Anonymous, 2012). The information 
on a barcode has many standards and the code is referred to as symbology (Anonymous, 
2012). There are about 20 standard symbologies being used such as UPC, EAN, ISBN, and 
PDF 417 (Yam, Takhistov, & Miltz, 2005). UPC stands for “Universal Product Code”, was 
introduced in the 1970s, and is primarily used by grocery stores for inventory, stock 
reordering, and checkout (Yam et al., 2005). Barcodes are optically scanned using a laser 
requiring line of sight of the barcode or magnetically scanned using a swipe reader 
(Anonymous, 2012). 
Linear barcodes are limited in size and the amount data stored (Yam et al., 2005). 
Technology has been improving and the need to store more information on a barcode is 
becoming more acute. New barcodes have been developed to store more information. One 
of these new standards is PDF 417, where PDF stands for Portable Data File (Yam et al., 





(Anonymous, 2012). Another 2-D matrix barcode standard is ECC200 which is the standard 
that GS1 uses (GS1, Unknowna; TEC-IT, 2014). 
Radio frequency identification (RFID) is another way to store and retrieve 
information about a product. RFID is able to read/write information to or from the tag 
through a reader like a linear barcode reader except it uses radio frequency (Davison, 2011). 
The tag consists of an antenna and a chip where the information is stored. The tag can be 
active, passive, or semi-passive (Kabachinski, 2005). An active tag has a battery which makes 
it a larger and a more expensive tag as compared to a passive tag (Want, 2006). The tag is 
attached to the item or package. 
There are low (<135 KHz, ~18"), high (13.56 MHz, ~3'), ultrahigh (890-930 MHz, 
~15 to ~30'), and microwave (2.45 GHz, ~3') frequency tags and readers (Kabachinski, 
2005). The higher the frequency of the tag, the higher the read rates. The read range of each 
tag is related to the higher frequency range except for microwave where the read range is 
similar to the HF tags (Kabachinski, 2005). The tag classes are 0 through 4 with tag class 0 
being read-only tags preprogrammed at the manufacturing plant. Tag class 4 are read/write 
tags and have integrated transmitters that can communicate with other tags and devices. Tag 
class 1 is a write-once tag that can be written to once by the manufacturer or user and can be 
read multiple times. Tag class 2 is a read/write tag with more memory and can be written to 
multiple times by manufacturer or user. Tag class 3 is a read/write tag that can contain 
onboard sensors.  
 Another method of knowing something about an object is to know its history, such 
as where an object originated and where it has been. In the art world this is known as 





history of the animal and its origins. This is product tracing as the pedigree accompanies the 
animal from buyer to seller and so forth. 
By attaching a serial number to an object and recording on paper or in an electronic 
format the object’s serial number, origin and owners, we have created a pedigree for that 
object. When we receive this object, we will know its provenance or pedigree. The cost of 
the pedigree is spread from buyer to seller and so forth which makes it practical for real-time 
access and it does not require a database for storage. However, as we know from in the art 
and breeding world, pedigrees can be faked and the product the pedigree is supposed to 
represent is counterfeit. 
2.7 Pedigree System 
Before 1987, there were five days of a Congressional hearing that resulted in a 
subcommittee formal report with the following concerns:  
 the existence of a drug wholesale submarket prevents knowing the source of 
the drug (Drabiak, 2005);  
 subpotent or adulterated drugs may enter the USPSC through the 
reimportation of drugs (Drabiak, 2005); 
 manufacturer representative’s free samples to physicians may encourage drug 
adulteration and/or misbranding (Drabiak, 2005);  
 health care institutions are releasing drugs into the market which could 
encourage drug diversion (Drabiak, 2005);  
 persons from foreign countries are counterfeiting brand name drugs which 
promotes subpotent and impotent drugs that compete with American market 
and tarnish the good name of legitimate products in those countries 
(Drabiak, 2005).  
 
The result of the report was the passing of The Prescription Drug Marketing Act of 
1987 (PDMA). PDMA was proposed based upon those hearings and signed into law on 
April 22, 1988 by the president. In the United States, PDMA was the first attempt to secure 
the PSC. A part of the PDMA was to initially establish a federal pedigree program which was 





Before 1987, each transaction would only include the current sales information and 
none of the sales history information. So by the secondary wholesaler there was no record 
where the drugs came from. PDMA required a sales transaction history to accompany the 
drugs that were being bought which created the sales history or pedigree for the drugs being 
bought (Thaul, 2013). (see Diagram 2) 
Due to industry objections, the FDA delayed the effective date of the PDMA of 
1987 regulations for several years until December 2006 (NABP, 2013). Because the federal 
pedigree program was delayed, the states started to require stronger laws in regards to their 
PSC (NABP, 2013). In 1992, Florida created its own pedigree system and requirements 
(Stovall, 2006). However, counterfeit drugs continued to be a problem in Florida (Stovall, 
2006) and the Florida legislation created the Prescription Drug Protection Act (FPDPA) of 
2003  based on the recommendations of a grand jury convened by then Governor Bush. 
FPDPA was amended in 2005 to allow electronic as well as paper pedigrees and its final act 
















































Figure 22     PDMA Pedigree Requirements After 1987
 
After much delay and with the Florida experience with corrupt wholesale distributors 
in 2003, the FDA announced in 2006 that it would require pedigrees from the wholesalers 
starting on December 1, 2006 (Young, 2006). There were objections to the pedigree 
requirement by a group of wholesalers known as the RxUSA. A federal rule and some states 
regulations did not require an authorized distributor of record (ADR) to provide a pedigree 





to the secondary wholesalers. This would have created a situation where the secondary 
wholesalers were required to give their buyers a pedigree which they did not have, which 
created an impasse. The pedigree requirement of the PDMA for secondary wholesalers 
would have put thousands of them out of business. Thus, on December 5, 2006 a federal 
district court judge delayed the implementation of the federal pedigree for the above reasons. 
Meanwhile in other states, by 2012 twenty-nine states had adopted, proposed, or 
enacted state or board regulations in regards to the use of drug pedigrees (HDMA, 2014). In 
addition, 18 states had enacted drug pedigrees. In 2004, California passed a pedigree law that 
would have an effective date as January 1, 2005 and two enactment dates (Messplay, 2014). 
The first enactment date was January 1, 2007 for wholesale distributors and January 2008 for 
the pharmacies of the state. Under the California law, the pedigree would be electronic, 
manufacturers would initiate the pedigree, and the pedigree to be serialized, and no 
manufacturer or wholesaler or pharmacist would be allowed to buy or sell drugs without a 
pedigree.  
Because of industry input, the California legislators passed multiple delays of 
pedigree law implementation until 2016 and 2017 which were the final dates. In addition, in 
March 2007 California's Board of Pharmacy stated that the GS1 EPCglobal Drug Pedigree 
Standard meets the requirements of the California pedigree law (Messplay, 2014). Thus, GS1 
Drug Pedigree Messaging Standard (DMPS) based on XML language became the standard 
because all drugs coming in and going out of California required a pedigree (EPCglobal, 
2007).  
The Food and Drug Administration Amendments Act of 2007 (FDAAA ; Public 
Law 110-85) allows the FDA to set standards for identification, validation, authentication, 





GOVERNMENT PRINTING OFFICE, 2013). The Food and Drug Administration Safety 
and Innovation Act (FDASIA, Public Law 112-144) of 2012, under Title VII, provided the 
FDA the authority that requires domestic and foreign drug manufacturers that sell 
pharmaceutical drugs and devices in the United States to register and be inspected by the 
FDA. The registration of domestic and foreign manufacturers required an electronic 
database to be created to maintain the registration information of the manufacturers. In 
addition, the FDA was given the authority to refuse the import by foreign or domestic 
manufacturers if inspections of their manufacturing facility was delayed, limited, or denied. 
This lasted until November 27, 2013, when the Drug Quality and Security Act 
(DSQA, Public Law 113-54) (Upton, 2013) was signed by the U.S. president. Since DSQA is 
the law in all states, we will focus our attention on Title II of the DSQA which is called Drug 
Supply Chain Security Act (DSCSA, Sec. 201). The DSCSA is a pedigree and product 
identifier verification system. The following will be a discussion of the DSCSA analysis, 





3. DSCSA Analysis, Modeling, and Implementation 
Since DSCSA will replace all other track, trace, and pedigree systems in the United 
States, especially the California pharmaceutical drug E-Pedigree system {DSCSA sec 585 
(a)}, we will focus our attention on DSCSA and determine the approach that will taken by 
this act. DSCSA gives the FDA the authority to build an interoperable system to trace 
pharmaceutical products in the USPSC within ten years after the enactment of the DSCSA 
which was November 27, 2013. 
3.1 DSCSA Requirements 
DSCSA is in its beginning stage of development as the FDA completed its first 
required task of the act by gathering comments from stakeholders and pharmaceutical 
community which was completed on April 21, 2014. The second task completed by the FDA 
was the public guidance document published in June 2014 to support the identification of 
illicit products and notification. The FDA is to complete the third task by November 2014, 
which is the published draft guidance document that provides standards for the 
interoperable exchange of transactional information, history, and statement in paper or 
electronic form. There are many more requirements due by January 1, 2015 by all trading 
partners which will be explained later. The FDA will establish a database for the purpose of 
registering wholesale distributors by January 1, 2015. Other tasks of note are the pilot 
programs that can begin after January 1, 2015.  
The analysis of the USPSC under the DSCSA will be conducted at a high level 
depicting the forward flow of the products and the requirements dictated by the DSCSA. It 
is beyond the scope of this thesis to do an exhaustive depiction of the effects on the USPSC 





change. The following image is a project plan indicating the high level tasks that are to be 
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3.2 DSCSA Definitions 
There are many definitions in the DSCSA. DSCSA definitions are found in the 
DSCSA Section 581. In the following definitions, we explain the major definitions of this act 
and leave the rest to the reader. We start with the trading partner definition as it sets the 





DSCSA defines USPSC trading partners. DSCSA requires all trading partners to be 
registered by the state or by the U.S. government (FDA). In addition, all trading partners in 
the USPSC can only do business with other trading partners who are authorized by being 
registered by the state or by the FDA {sec. 581(2)}. This requirement will make the USPSC 
a closed system. 
The trading partners of the USPSC are defined to be manufacturer, wholesale 
distributor, third-party logistics provider (3PLs), repackager, and dispenser {sec. 581(23)}. 
Authorized distributor of record (ADR) is defined to be "those distributors with whom a 
manufacturer has established an ongoing relationship to distribute such manufacturer's 
products" (2013, sec. 583 (b)). Wholesale distributors can be ADR and non-ADR. 
Dispensers are defined as retail pharmacy, hospital pharmacy, and a group of chain 
pharmacies under common ownership and control that don't act as a wholesale distributor 
and exempts a person who dispenses only products used by animals {sec. 581(3)}. 
A manufacturer is defined to be 
 "a person that holds an application approved under section 505 or a license 
issued under section 351 of the Public Health Service Act for such product, 
or if such product is not the subject of an approved application or license, 
the person who manufactured the product;" (2013, sec. 581(10)(A)) 
 "a co-licensed partner of the person described in subparagraph A that 
obtains the product directly from a person described in this subparagraph or 
subparagraph A. or C.; or" (2013, sec. 581(10)(B)) 
 "an affiliate of a person described in subparagraph A. or B. that receives the 
product directly from a person described in this subparagraph or 
subparagraph A. or B." (2013, sec. 581(10)(C)).  
 
A repackager is defined to be "a person who owns or operates an establishment that 
repacks and relabels a product or package for" (2013, sec. 581(16)) "further sale; or" (2013, 





Wholesale distributors are defined by the individual state laws. DSCSA has placed 
restrictions on who can be an owner of a wholesale distributor business. "The standards 
established under subsection (a) shall include requirements to prohibit a person from 
receiving or maintaining licensure for wholesale distribution if the person" (2013, sec. 
583(d)) 
 "has been convicted of any felony for conduct relating to wholesale 
distribution, any felony violation of subsection (i) or (k) of section 301, or 
any felony violation of section 1365 of title 18, United States Code, relating 
to product tampering; or" (2013, sec. 583(d)(1)) 
 "has engaged in a pattern of violating the requirements of this section, or 
State requirements for licensure, that presents a threat of serious adverse 
health consequences or death to humans" (2013, sec. 583(d)(2)). 
 
From above, we have defined the main trading partners. The following are the 
definitions needed to further define the requirements of the USPSC under the DSCSA. 
DSCSA will define product and the product identifier used to verify the product. DSCSA 
will define the following: standard numerical identifier (SNI), package, smallest saleable unit, 
homogenous case, transaction, transaction statement, history, and information. The 
following will cover the DSCSA definitions of affiliate, suspect product, illegitimate product, 
and to verify or verification.  
A product identifier is defined as 
a standardized graphic that includes, in both human-readable form and on a 
machine-readable data carrier that conforms to the standards developed by a widely 
recognized international standards development organization, the standardized 
numerical identifier, lot number, and expiration date of the product (2013, sec. 
581(14)). 
Product identifiers will be a part of the 1-D and 2-D data matrix barcode when 





Basically, a product means a prescription drug in its final form, such as a tablet or 
capsule that would be given to a patient for consumption. All other prescription drugs 
defined as biologics, blood or blood components, radioactive drugs, imaging drugs, 
intravenous drugs, any medical gas, etc. are excluded. A more complete definition of 
"Product" can be found in {sec. 581(13)}. 
S standard numerical identifier (SNI) is defined to be:  
a set of numbers or characters used to uniquely identify each package or 
homogenous case that is composed of the National Drug Code that corresponds to 
the specific product (including the particular package configuration) combined with a 
unique alphanumeric serial number of up to 20 characters (2013, sec. 581(20)). 
A package is defined to be "the smallest individual saleable unit of product for 
distribution by a manufacturer or repackager that is intended by the manufacturer for 
ultimate sale to the dispenser of such product" (2013, sec. 581(11)(A)). 
A smallest saleable unit is defined as "the smallest container of product introduced 
into commerce by the manufacturer or repackager that is intended by the manufacturer or 
repackager for individual sale to a dispenser" (2013, sec. 581(11)(B)). 
A homogenous case is defined to be "a sealed case containing only product that has 
a single National Drug Code number belonging to a single lot" (2013, sec. 581(7)). 
A transaction is defined to be "the transfer of product between persons in which a 
change of ownership occurs" (2013, sec. 581(24)(A)). 
Transaction history is defined as "a statement in paper or electronic form, including 
the transaction information for each prior transaction going back to the manufacturer of the 
product" (2013, sec. 581(25)). 





 "the proprietary or established name or names of the product;" (2013, sec. 
581(26)(A)) 
 "the strength and dosage form of the product;" (2013, sec. 581(26)(B)) 
 "the National Drug Code number of the product;" (2013, sec. 581(26)(C)) 
 "the container size;" (2013, sec. 581(26)(D)) 
 "the number of containers;" (2013, sec. 581(26)(E)) 
 "the lot number of the product;" (2013, sec. 581(26)(F)) 
 "the date of the transaction;" (2013, sec. 581(26)(G)) 
 "the date of the shipment, if more than 24 hours after the date of the 
transaction;" (2013, sec. 581(26)(H)) 
 "the business name and address of the person from whom ownership is 
being transferred; and" (2013, sec. 581(26)(I)) 
 "the business name and address of the person to whom ownership is being 
transferred" (2013, sec. 581(26)(J)). 
 
Transaction statement is defined as "a statement, in paper or electronic form, that 
the entity transferring ownership in a transaction—" (2013, sec. 581(27)) 
 "is authorized as required under the Drug Supply Chain Security Act;" (2013, 
sec. 581(27)(A)) 
 "received the product from a person that is authorized as required under the 
Drug Supply Chain Security Act;" (2013, sec. 581(27)(B)) 
 "received transaction information and a transaction statement from the prior 
owner of the product, as required under section 582;" (2013, sec. 581(27)(C)) 
 "did not knowingly ship a suspect or illegitimate product;" (2013, sec. 
581(27)(D)) 
 "had systems and processes in place to comply with verification requirements 
under section 582;" (2013, sec. 581(27)(E)) 
 "did not knowingly provide false transaction information; and" (2013, sec. 
581(27)(F)) 
 "did not knowingly alter the transaction history" (2013, sec. 581(27)(G)). 
 
One of the exceptions to the above transaction statement definition is when the 
wholesale distributor has purchased the product directly from the manufacturer, the 
transaction statement will "state that such wholesale distributor, or a member of the affiliate 
of such wholesale distributor, purchased the product directly from the manufacturer, 
exclusive distributor of the manufacturer, or repackager that purchased the product directly 





Affiliate is defined as "a business entity that has a relationship with a second business 
entity if, directly or indirectly:" (2013, sec. 581(1)) 
 "one business entity controls, or has the power to control, the other business 
entity; or" (2013, sec. 581(1)(A) 
 "a third party controls, or has the power to control, both of the business 
entities" (2013, sec. 581(1)(B)). 
 
 Verification or verify is define as 
determining whether the product identifier affixed to, or imprinted upon, a 
package or homogeneous case corresponds to the standardized numerical identifier 
or lot number and expiration date assigned to the product by the manufacturer or 
the repackager, as applicable in accordance with section 582 (2013, sec. 581(29)). 
Suspect product is defined to be a product that is potentially counterfeit, diverted, 
stolen, or adulterated and may have been part of fraudulent transactions or basically unfit for 
distribution due to adverse health consequences or death to humans {2013, sec. 581(21)}.  
Illegitimate product is defined to be counterfeit, diverted, stolen, or intentionally 
adulterated and has been part of fraudulent transactions or basically unfit for distribution 
due to adverse health consequences or death to humans {2013, sec. 581(8)}. 
For the sake of convenience, I will define transaction records to be transaction 
statement, transaction information, and transaction history.  
3.3 Trading Partners Registrations and License 
According to Title VII of The Food and Drug Administration Safety and Innovation 
Act of 2012 (FDASIA, Public Law 112-144), within a two year period after July 9, 2012, all 
domestic and foreign manufacturers doing business in the U.S. have to be registered and 
provided a facility identifier by the FDA. According to {sec 584(a)},  all 3PLs doing business 





of November 2014 {sec. 584 (b)} and all wholesale distributors doing business in the 
USPSC will report to the FDA to be registered by the beginning of January 1, 2015. {sec. 
204 (a)(2)(B)} If the state doesn't register 3PLs, then the FDA will provide a license for the 
3PLs. {sec. 584(a)(B)} All dispensers are to be registered by the state {2013, sec. 581(9)(C)}.   
3.4 Product Tracing Systems Requirements 
The wholesale distributor, dispenser, and secondary wholesale distributor will have a 
transaction records storage system. The transaction records storage system can be an 
electronic database. The electronic database can be used to store transaction statement (TS), 
information (TI), and history (TH) for each transaction for the purpose of verification of a 
product. The manufacturer and repackager will have a transaction records and product 
identifier storage systems for the purpose of verification of a product {2013, sec. 




































Figure 24     Transaction Records Flow
 
3.5 Transaction Records and Product Identifier Requirements 
3.5.1 Manufacturer 
In the case where the product and transaction records trail begins with the 
manufacturer, it only makes sense that the TH would only contain current TS and TI that 
will be sent in a single document to the recipient of the shipment of products from the 
manufacturer {2013, sec. 582(b)(1)(A)(i)}.  However, by no later than January 1, 2015, the 
manufacturer is not allowed to accept ownership of any product without the transaction 
records on or before taking ownership and only from authorized trading partners {sec. 
582(c)(1)(A)}. All transaction records maintained by manufacturers must be kept for a 





Manufacturers will have systems in place by January 1, 2015 to allow for verification 
of suspect products or a verification requested by the Secretary of Health and Human 
Services (Secretary) or other Federal or State official  for products that has been determined 
to be in their possession or control {sec. 582(b)(4)} or into the investigation into possible 
suspect products. The investigational records of a suspect product will be kept for a period 
of six years after the conclusion of the investigation {sec. 582(b)(4)(A)(iii)}. An electronic 
database can be used to maintained the transaction records for verification purposes {2013, 
sec. 582 (b)(4)(D)}. 
By November 2017, manufacturers will provide an electronic format of the 
transaction records {2013, sec. 582(b)(1)(C)(i)}, The exception is that the manufacturer may 
provide paper format of the transaction records "to those licensed health care practitioner 
authorized to prescribe medication under state law or licensed individual under the 
supervision or direction of such a practitioner show dispenses product in the usual course of 
professional practice"  (2013, sec. 582(b)(1)(C)(ii)).   
In addition, by November 2017 a product identifier will be affixed or imprinted to 
each package and homogenous case of a product in a transaction entering the PSC {sec 
582(b)(2)(A)}. Furthermore, the manufacturer will maintain the product identifier 
information for a period of six years after the transaction date {sec 582(b)(2)(A)}. The 
exception is where a package with a required SNI doesn't require a unique device identifier 
{sec 582(b)(2)(B)}. 
Products that are returned are classified as saleable and nonsaleable. Saleable returns 
that the manufacturer plans to return to commerce will have verified the product identifier 
and SNI for each homogenous case or not a homogenous case on each package {sec 





seller, such as manufacturer, wholesale distributor,  repackager, or to a person acting on the 
behalf of such person which includes returns processor, will not have to include transaction 
records upon transfer {2013, sec 582(b)4)(F)}. 
 3.5.2 Wholesale Distributor 
The wholesale distributor (ADR and non-ADR) is not allowed to accept ownership 
of any product without the transaction records on or before taking ownership and from only 
an authorized trading partner by January 1, 2015 {sec. 582(c)(1)(A)}. The exception will be 
in the case where the product was purchased from a manufacturer, then only TS and TI is 
required. Additionally, six years after the enactment of the DSCSA in November 2019, the 
wholesale distributor will not be allowed to have product transactions without a product 
identifier {sec. 582(c)(2)}. 
The wholesale distributor will provide to the buyer the standard transaction records 
of the product being shipped. If the wholesale distributor had purchased directly from the 
manufacturer, the TS will state that the wholesale distributor bought the products directly 
from the manufacturer {sec. 582 (c)(1)(A)(ii)(I)(aa)(AA)}.  As like the manufacturer, the 
wholesale distributor will keep the transaction records for a period of six years {sec. 582 
(c)(1)(A)(v)}. 
The wholesale distributor by January 1, 2015 will have in place systems to allow for 
verification of suspect products or a verification requested by the Secretary for products that 
are in their possession or control {2013, sec 582(c)(4)}. The records of the investigation will 
be kept for a period of six years after the conclusion of the investigation {sec. 582 
(c)(4)(A)(iii)}. An electronic database can be used to maintain the transaction records for 






By January 1, 2015, the dispenser will not accept any product without the transaction 
records {sec. 582(d)(1)(A)} and only from an authorized trading partner {sec. 582 (d)(3)}. 
When the dispenser transfers the ownership of products to another trading partner 
(excluding patients and returns), the transaction records will be transferred on or before the 
shipment of product to the new owner. A dispenser is not allowed to accept any product 
from an authorized trading partner that does not have a product identifier encoded by 
November 2020. Dispensers can enter into an agreement with a third party (including a 
wholesale distributor) for the purpose of maintaining transaction records as required by the 
DSCSA except that the obligation and responsibility of the system is still with the dispenser.  
In the case of saleable returns, the returned product may be sent back to the trading 
partner that sold them the product without having to produce the transaction records. In the 
case of the nonsaleable returns, a dispenser may return the product back to the 
manufacturer, the wholesale distributor, the repackager, a returns processor, or a person 
representing such a person without providing transaction records {2013, sec. 582(d)(1)(B)}. 
By January 1, 2015, a dispenser is required to have systems in place for the purpose 
of verification of suspect products or to allow inquiries by the governmental and state 
agencies {sec. 582(1)(D) and 582(4)}. In the case of an investigation of  {sec. 582(4)((A)(iv)} 
and disposition of {sec. 582(4)((A)(v)} a suspect product, all records of the investigation will 
be kept for a period of six years after the conclusion of the investigation. A secure electronic 
database can be used for the purpose of maintaining the transaction records for verifications 







A repackager as defined by {sec. 581(16)(A)} and by January 1, 2015 will not accept 
product from an unauthorized trading partner {sec. 582(e)(3)} without the transaction 
records. When the ownership of a product is being transferred from the repackager to 
another authorized trading partner, the repackager is responsible to transfer the transaction 
records to the new owner on or before the time of the transaction {sec. 582(e)(1)(A)(i, ii, 
iii)}. By November 2018, a repackager will affix or imprint a new product identifier to each 
package or homogenous case that will be introduced into the USPSC {sec. 582(e)(2)(A)(i)}. 
The repackager will maintain the information on the new product identifier for a period of 
six years after the date of the transaction {sec. 582(e)(2)(A)(ii)}. When the repackager breaks 
up a package that had an original manufacturer product identifier affixed or imprinted upon 
it, the repackager will maintain the association between the original manufacturer product 
identifier and the repackager product identifier for a period not less than six years {sec. 
582(e)(2)(A)(iv)},  
By January 1, 2015, repackager will have a system in place for the purpose of 
verification of suspect products that is in the repackager’s control or possession or upon the 
request of verification from the Secretary which has determined the repackager is in control 
or in possession of suspect product {sec. 582(e)(4)(A)(i)}. Investigational records of a 
suspect product will be maintained for a period of six years after the investigation has 
concluded {sec. 582(e)(4)(A)(iii)}. 
At the start of November 2018, a repackager receiving a request for verification of a 
product by the requesting trading partner by using the product identifier including the SNI 
will notify the requestor within 24 hours or a time period deemed reasonable by the 





in possession or control of the product in question. If the repackager deemed the product 
being verified to be illegitimate, the repackager will notify the requestor and start the 
investigation of a suspect product as described in {2013, sec. 582 (e)(4)(A)}. 
3.6 Verification of Product Identifiers and SNI Requirements 
Starting in November 2017, a manufacturer will process a verification request from 
an authorized repackager, wholesale distributor, or dispenser that is in control or possession 
of a product that it believes was created by the manufacturer. The manufacturer that receives 
the request will verify the product identifiers and SNI within 24 hours after receiving the 
request or a time period deemed reasonable by the Secretary to notify the requestor as to the 
status of product identifier and SNI. In the case where the product identifier does not 
correspond to the manufacturer's records of product identifiers, then the product is believed 
to be suspect and the requestor is notified as such {2013, sec 582(b)(2)(C)}. (see Figure 25) 
Starting in November 2018, a repackager will process a verification request from an 
authorized manufacturer, wholesale distributor, or dispenser that is in control or possession 
of a product that it believes to be repackaged by the repackager. The repackager that receives 
the request will verify the product numbers and SNIs within 24 hours after receiving the 
request or a time period deemed reasonable by the Secretary to notify the requestor as to the 
status of product identifier and SNIs. In the case where the product identifier does not 
correspond to the repackager records of product identifiers, then the product is believed to 



































Verification starting on November 2017
Verification starting on November 2018
 
3.7 Suspect or Illegitimate Product Procedures Requirements 
3.7.1 Manufacturer 
Once the manufacturer has determined or has been notified by the Secretary that a 
suspect product is in their possession, the product is quarantined. An investigation is started 
with the manufacturer’s trading partners to determine whether the product in question is 
illegitimate or not. The investigation steps are to validate the transaction records that are in 
the possession of the manufacturer of the suspect product. Starting in November 2017, the 
investigational steps will include the validation of product at the package level and SNI. If 
one of the results of the investigation is to clear the product in question, then the Secretary is 





If the product in question is deemed to be illegitimate, a sample of the illegitimate 
product is taken for further physical examination or laboratory analysis by the manufacturer 
or the Secretary. The illegitimate product is disposed of in a matter appropriate to the 
manufacturer. The Secretary and all immediate trading partners are notified within 24 hours 








































Figure 26     Manufacturer  Verification of Suspect or Illegitimate Product
 
3.7.2 Wholesale Distributor 
Once the wholesale distributor has determined or has been notified by the Secretary 
that a suspect product is in their possession, the product is quarantined. An investigation is 
started in coordination with  the wholesale distributor’s trading partners to determine 
whether the product in question is illegitimate or not. The investigation steps are to validate 





product. Starting in November 2019, the investigational steps will include the validation of 
product at the package level and SNI. If one of the results of the investigation is to clear the 
product in question, then the Secretary is notified of the product clearance and then the 
product is released to the market. 
In coordination with the manufacturer, if the product in question is deemed to be 
illegitimate, a sample of the illegitimate product is taken for further physical examination or 
laboratory analysis by the manufacturer or the Secretary. The illegitimate product is disposed 
of in a matter appropriate to the wholesale distributor. The Secretary and all immediate 
trading partners are notified within 24 hours of determination of the product to be 


















































Once the dispenser has determined or has been notified by the Secretary that a 
suspect product is in their possession, the product is quarantined. An investigation is started 
with the dispenser’s trading partners to determine whether the product in question is 
illegitimate or not. The investigation steps are to validate the transaction records that are in 
the possession of the dispenser of the suspect product. Starting in November 2020, the 
investigational steps will include the validation of product at the package level, SNI, and lot 
number. If one of the results of the investigation is to clear the product in question, then the 
Secretary is notified of the product clearance and then the product is released to the market. 
In coordination with the manufacturer, if the product in question is deemed to be 
illegitimate, a sample of the illegitimate product is taken for further physical examination or 
laboratory analysis by the manufacturer or the Secretary. The illegitimate product is disposed 
of in a matter appropriate to the dispenser. The Secretary and all immediate trading partners 
















































Figure 28     Dispenser  Verification Of Suspect or Illegitimate Product
 
3.7.4 Repackager 
Once the repackager has determined or has been notified by the Secretary that a 
suspect product is in their possession, the product is quarantined. An investigation is started 
with the repackager’s trading partners to determine whether the product in question is 
illegitimate or not. The investigation steps are to validate the transaction records that are in 
the possession of the repackager of the suspect product. Starting in November 2018, the 
investigational steps will include the validation of product at the package level and SNI. If 
one of the results of the investigation is to clear the product in question, then the Secretary is 
notified of the product clearance and then the product is released to the market. 
In coordination with the manufacturer, if the product in question is deemed to be 





laboratory analysis by the manufacturer or the Secretary. The illegitimate product is disposed 
of in a matter appropriate to the repackager. The Secretary and all immediate trading 
partners are notified within 24 hours of determination of the product to be illegitimate. (see 
Figure 29)  
All trading partners’ investigational records will be kept for a period of six years at 














































Figure 29     Repackager  Verification Of Suspect or Illegitimate Product
 
 
3.8 Electronic Database 
All of the trading partners of the USPSC, excluding 3PLs, are required to have 
systems in place by January 1, 2015 to maintain transaction records for a period of six years 





According to the DSCSA, an electronic database can be used to maintain these records and 
can be developed and maintained by the trading partners or by a third part vendors. 
Although a third party can maintain and operate a database, it is still the responsibility of 
each trading partner to ensure the capability of its database to be able to satisfy a request for 
verification. 
What might this database look like? Well, DSCSA does stipulate what the TS, TI, 
and TH contains. TS is a document containing required language and TI must contain 
certain fields. Additional information would be the product identifiers that must be 
maintained by the manufacturer and the repackager for verification and for a period of six 
years. Furthermore, the repackager must maintain the relationship between the manufacturer 
product identifier and the new product identifier that the repackager has attached to the 
package and homogenous case as required. The transaction history records will include all  
the TS and TI transactions that have occurred before arriving at its current location in the 
USPSC. From this information, the transaction history would be a series of TI and TS 
associated with each transaction. The following is a possible logical model Entity-
Relationship diagram (ERD) design for the DSCSA schema. All ERDs were created using 




































3.8.1 Manufacturer Logical Model ERD 
The manufacturer logical model ERD would contain the Transaction History table 
(tbl_TH), Transaction Statement table (tbl_TS), and Transaction Information table (tbl_TI). 
Tbl_TH tracks the old TS and TI information going back to the manufacturer if applicable 
and the current TI and TS associated with the current transaction. 
Minimum cardinality for each instance in the tbl_TH would be at least one instance 





many instances in the tbl_TS. The logical model ERD design between tbl_TH and tbl_TS 
would be the following: (see Figure 31) 
Transaction _History Transaction _Statement
Figure 31     Logical Model tbl_TH to tbl_TS
 
The reverse of the relationship would be one or more instances in the tbl_TS would 
relate to one instance in the tbl_TH.  
A single transaction would contain one tbl_TS instance for the shipment and one or 
more TIs to reflect the contents of the shipment. The minimal cardinality would be one 
instance in the tbl_TS that would relate to one instance in the tbl_TI. The maximum 
cardinality between tbl_TS and tbl_TI would be one instance in the tbl_TS that would relate 
to many instances in the tbl_TI. The logical model ERD would look like Figure 32: 
Transaction _Statement Transaction_Information
Figure 32     Logical Model tbl_TS to tbl_TI
 
In reverse, one or more instances in tbl_TI would relate to one instance in the 
tbl_TS.  
By combining the two logical ERDs (Figure 31 and Figure 32), the resultant would 





Transaction _History Transaction_Statement Transaction_Information
Figure 33     Logical Model tbl_TH to tbl_TS to tbl_TI
 
After November of 2017, the manufacturer is required to affix or imprint a product 
identifier to each package and homogenous case of a product and maintain the records of 
these product identifiers. The product identifier includes standardized numerical identifier 
(SNI), lot number, and expiration date of the product. Since the SNI contains the package 
NDC number, the name of the drug and package information is acquired from it. 
The minimum cardinality of a product identifier table (tbl_PI) would be one instance 
of the product identifier that would relate to one instance of SNI table (tbl_SNI). The 
maximum cardinality would be one instance of a product identifier that would relate to one 
or more instances of SNI. (see Figure 34) 
Product_Identifiers SNI
Figure 34     Logical Model tbl_PI to tbl_SNI
 
In reverse, one or more instances in tbl_SNI would relate to one instance in the 
tbl_PI. 
For example a non-homogenous case of product could contain multiple packages 
each with their own SNI, lot number, and expiration date. Another example would be a 
homogenous case of product that would relate to a different SNI with the same lot number 





Although it is not required by DSCSA, we will tie the transaction history, statement, 
and information to the product identifiers. The minimal cardinality would be for a single 
instance in the tbl_TH to refer to at least one instance of product identifier. The maximum 
cardinality would be for one instance in the tbl_TH there would be many instances in the 
tbl_PI. The logical model ERD would look like the following: (see Figure 35) 
Transaction_History Product_Identifiers
Figure 35     Logical Model tbl_TH to tbl_PI
 
In reverse, one or more instances in tbl_PI would relate to one instance in the 
tbl_TH. 
Let us combine all the manufacturer logical model ERDs together and they would 
look like Figure 36: 
Transaction _History Transaction_Statement Transaction_Information
Product_Identifiers SNI
Figure 36     Combined Logical Model 
 
In the tbl_TI, there is a requirement of the senders and receiver information. 





times. So, the business name, address, contact person information would be used over and 
over again for each transaction associated with them. This implies that one entry in the 
Transaction Address (tbl_Address) table could be mapped to multiple entries in the tbl_TI 
for sender and receiver. (see Figure 37) 
Transaction_Information Transaction_Address
Figure 37     Logical Model tbl_TI to tbl_Address
 
The tbl_TI is required to have several columns such as product name, strength, 
dosage, package NDC, container size, number of containers, lot number, transaction date, 
shipping date, sender information, and receiver information. The tbl_Address would have 
the following columns: business name, street address, city, state, postal code, country, 
contact name, contact title, contact phone number, contact email, contact URL, address 
identification, license number, license state, and license agency. Most of the columns are self 
explanatory except for address identification which could be the plant number, GS1 Global 
Location Number (GLN), and any other means to identify the address. (see Figure 38) 
Each entry in the tbl_TH would map to at least one or more product identifiers. It is 
not required to maintain a relationship between the tbl_TH and the tbl_PI. However, it 
would be nice for verification purposes to be able to track what product identifiers are 
related to a particular transaction record. (see Figure 38)    
Each product identifier is mapped to one lot number, expiration date, and standard 
numerical identifier (SNI) for each package and/or homogenous case. In the situation of a 
homogenous case, one product identifier could be attached to the case with multiple 





relationship of one product identifier to one or more SNIs. This implies that the product 
identifier table entry would be mapped to one or more entries in the SNI table. (see Figure 
38) 
The tbl_TH would have a primary key which would be a sequence number and we 
will call it Transaction_ID. The other column in this table could be Transaction_Date. 
Another column might be the Transaction_Document with values such as "invoice", 
"purchase order", "shipping number", or "return authorization number". Another column 
could be Transaction_Document_No which would be the document number such as the 
invoice number or purchase order which is related to Transaction _Document. Another 
column that might be needed is the Transaction_Type which would have values of "sale", 
"return", "transfer", or others. (see Figure 38) 
The tbl_TS would have a primary key called Statement_ID. The other column would 
be the Statement_Document. The statement document could be a scanned, text type, or 























































3.8.2 Repackager ERD 
The repackager logical model ERD would be the same as the Manufacturer logical 
model ERD except for the additional  tables required for mapping the repackager new 
product identifiers to the original manufacturer product identifiers. The repackager logical 
model ERD would have the same tbl_TH, tbl_TS, tbl_TI, tbl_PI, and tbl_SNI tables and 
relationships as the manufacture's logical model ERD. However, the two new tables would 





The additional tables in the repackager logical model ERD have to do with the 
DSCSA requirement. Repackagers must maintain records for a period of six years when they 
attach a new product identifier to a product that had a manufacturer product identifier 
attached to it. Repackagers have to show the relationship between the new repackager 
product identifier to that of the manufacturer product identifier. An example of this 




Figure 39     Logical Model Repackager to Manufacturer Product Identifier 
 
For example, if the repackager splits the manufacturer case into two cases of equal 
quantity, then the manufacturer product identifier attached to the manufacturer case would 
have to be mapped to the two new repackager product identifiers. The repackager would 
have to keep a record of the remapped manufacturer product identifier to the two new 
repackager product identifiers for a period of six years.  
The above example explains the need for a foreign key in the repackager product 
identifier table to satisfy the requirement of mapping one manufacturer identifier to one or 





identifier table to the repackager product identifier would be one to many. In the case where 
the repackager were to consolidate the number of manufacturer cases to a single box for 
instance, then the relationship would be one repackager product identifier to many 
manufacturer product identifiers. Since both examples could exist, an intersection table 
would be required. Now the relationship between repackager product identifier to 
manufacturer identifier would be many to many. The above described relationship would 





Figure 40    Logical Model Repackager to Manufacturer Product Identifier with Intersection Table
 
The SNIs would be found in both manufacturer and repackager SNI tables and may 
be redundant but would help in the remapping of SNIs to repackager product identifiers as 
the repackager SNI table would have to contain the same SNIs in the manufacturer SNI 
table.  





































































3.8.3 Wholesale Distributor and Dispenser 
The wholesale distributor and dispenser logical model ERD would be the same 
because their responsibility would be to maintain the transaction records only. The logical 
model ERD would look like the following: (see Figure 42) 













































3.9 Product Identifier Verification Implementation 
3.9.1 Introduction 
On November 27, 2014, the FDA will produce a draft guidance document that 
creates standards for the transaction records being exchanged between trading partners in 
paper or electronic format. However, at this time there will not be any guidance documents 
to cover verification procedures that will be performed between trading partners. The only 
requirement is to create a system to allow verification by trading partners by January 1, 2015. 
The product identifier is used to verify that the product came from the manufacturer or 
repackager. We know from the DSCSA document that a product identifier will be a  
standardized graphic that includes, in both human readable form and on a machine 
readable data carrier that conforms to the standards developed by a widely 
recognized international standards development organization, the standardized 
numerical identifier, lot number, and expiration date of the product. (2013, sec. 
581(14))  
There are two internationally accepted standards: Electronic Data Interchange (EDI) 
and GS1 Global Data Synchronization Network (GDSN).  
3.9.2 Electronic Data Interchange (EDI) 
EDI is business-to-business (B2B) software that has been widely available since the 
1980s (Lim & Palvia, 2001) and developed under two main standards: American National 
Standards Institute (ANSI) X12 and United Nations/Electronic Data Interchange for 
Administration, Commerce, and Transport (UN/EDIFACT) (Kabak & Dogac, 2010). EDI 
is a paperless system that uses computers for the exchange of business documents such as an 





the Internet (Copeland, 1997; Kabak & Dogac, 2010; Lim & Palvia, 2001). The buyer creates 
an RFQ on their computer and EDI creates an electronic version of the RFQ and sends it to 
the seller’s computer system. The seller order entry system receives the PO electronically via 
their EDI software and processes it by updating their computer system and then sends an 
acknowledgement back to the buyer. The seller sends a quote back to the buyer and an 
acknowledgement is sent back to the seller of receipt. Then the buyer sends a PO to the 
seller and an acknowledgement is sent back. In addition, inventory replenishment systems 
and electronic funds transfers (ETFs) are part of EDI. The following is an example a basic 
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3.9.3 GS1 US 
 GS1 US is a not-for-profit organization that supplies the world's most accepted 
supply chain standards (GS1, Unknownd). These standards include globally unique 
numbering formats for identifying supply chain objects using barcodes and radio frequency 
identification tags (RFID)(GS1, Unknowne) . These standards are used for the storage of the 
identification numbers and data sharing. The main purpose of GS1 US is to organize 





Due to the FDA Amendments Act (FDAAA) of 2007 and FDA Safety and 
Innovation Act (FDASIA) of 2012 which directed the FDA to create unique device 
identification system for medical devices, GS1 became one of the accredited agencies for 
unique device identifiers (UDIs). UDIs will be created and maintained by device labelers 
according to global device identification standards maintained by the FDA-accredited issuing 
agencies. The FDA will maintain and operate the Global Unique Device Identification 
database (GUDID) for all UDI labeled devices. GDSN is the system used to populate the 
FDA GUDID. (MedTech, 2013) 
3.9.4 GS1 GDSN 
GS1 GDSN is a real time system that allows sellers and buyers to access and 
exchange product information (GS1, Unknownc). In our case, buyers and sellers are the 
trading partners as defined by the DSCSA. For the manufacturers to share product 
information via product identifiers, they are required to insert their data into the data pool. 
The data pool is a database of GS1 standardized product information that is use to maintain 
and operate as a data exchange between trading partners as part of the GDSN.  
The main purpose of GDSN is to store product data. GDSN can store up to 150 
different attributes of a product such as those contained in 1-D and 2-D matrix barcodes 
(GS1, Unknownb). Another purpose is to provide shared data access and timely notification 
of additions, deletions, and modification of product information to the trading partners. 
GDSN provides globally defined standards along with a common set of rules and definitions 
that are applied to data representation and database access. The network part of GDSN 
consists of a number of central databases (data pools). The GS1 Global Registry is the 
GDSN data pool that contains a list of registered users, users’ access rights to product 





the subscribers’ shared information. GDSN is monitored and maintained by the GS1 
Member Organization but is operated by a third party solution provider, or other 
independent authority (GS1, Unknownb). The following is a diagram of GDSN (GS1, 

















Figure 44     Global Data Synchronization Network
1. Load data: the seller registers product and company information to its data pool
2. Register data: a small subset of this data is sent to the GS1 Global Registry
3. Request subscription: buyer, via its own data pool, subscribes to receive buyers information
4. Publish data: seller data pool publishes the requested information to the buyer data pool
5. Confirm & Inform: Buyer sends a confirmation to the seller local data pool which informs them of the action taken.
5
Source: http://www.gs1.org/gdsn/how
Retrieved: July 4, 2014
 
3.9.5 EDI vs. GDSN for Product Verification 
EDI is used for B2B transactions for inventory, invoice, and payment purposes. 
GDSN is used for sharing product information between trading partners. Since we are going 






GS1 Global Trade Item Number (GTIN) is a unique number that identifies trade 
items throughout a supply chain (GS1, 2013d). A trade item can be a single item or a 
package configuration (case, carton, pallet). In addition, GTIN is a required component in 
GDSN. This requires the GTIN data in the barcode to be the same as the data stored in the 
GDSN databases. Thus, the GTIN value must be unique throughout the world. 
For the GTIN to be unique, each company using GDSN must buy a subscription to 
the GDSN services. After obtaining a subscription from the GS1 GDSN service, a company 
is given a company prefix which consist of a  GS1 Prefix and Company number (GS1, 
2013b). The company prefix consists of seven to eleven digits that are part of the GTIN data 
structure. A digit has a value of 0 through 9. The GTIN structure begins with a indicator 
digit followed by a company prefix, item reference number, and the check digit. A GTIN 
can be 8, 12, 13, or 14 digits long. The following is a breakdown of the GTIN structure 
(GS1, 2013d). (see Figure 45) 
Note: 0 - zero filled, N - digit, C - Check digit
Source: http://www.gs1us.org/Portals/0/gs1 us library/
standards/gs1 identification numbers/An Introduction to 
the Global Trade Item Number (GTIN).pdf
Retrieved: July 4, 2014
Figure 45     GTIN Structure 8-14
Type 1 2 3 4 5 6 7 8 9 10 11 12 13 14
GTIN-8 0 0 0 0 0 0 N N N N N N N C
GTIN-12 0 0 0 0 0 0 N N N N N N N C
GTIN-13 0 N N N N N N N N N N N N C
GTIN-14 N N N N N N N N N N N N N C
GTIN Digits
 
The digits between 2 and 13 (12 digits) are where the company prefix and item 





Note: Item Reference number begins at digit 13 and grow to the left
GS1 Company Prefix number begins at digit 2 and grows to the right 
Source: http://www.gs1.org/docs/gsmp/healthcare/GS1_Healthcare_GTIN _Allocation_Rules.pdf
Retrieved: July 4, 2014
Figure 46     Structure of a GTIN -14
Indictor Check 
Digit Digit





The larger the company prefix, the smaller number of products that can be 
identified. The following figure gives a breakdown (GS1, 2014). (see Figure 47) 
Source: http://www.gs1us.org/resources/standards/company-prefix
Retrieved: July 4, 2014





Seven Digits 0NNNNNN 100,000
Eight Digits 0NNNNNNN 10,000
Nine Digits 0NNNNNNNN 1,000
Ten Digits 0NNNNNNNNN 100
Eleven Digits 0NNNNNNNNNN 10
Figure 47     The GS1 Company Prefix
 
GTIN-14 could not be used to track National Package Drug Code which is ten digits 
in length and over 150,000 items as of May 19, 2014. Because there are a little over 78,000 
drug products in the product NDC data with over 7,000 labelers, a drug manufacturer or 
repackager could choose a seven-digit company prefix and would be able to identifier up 





could choose an eight-digit company prefix and would be able to track up to 10,000 
products. However, as a product identifier (GTIN-14) would have to exist for a period six 
years before being retired, a larger number for product identifiers may be required.  
3.9.7 Product Identifier (GTIN-14) 
Once the company has subscribed to GDSN and received their company prefix, the 
company will have the ability to create product identifiers (GTINs) and access the GS1 
standards. The product identifiers along with serial number, batch/lot number, and 
expiration date can be stored in the GDSN and displayed at the item and the package level 
via 1-D and 2-D barcodes which is a requirement of DSCSA sec. 582(a)(9). A 2-D data 
matrix will be affixed to the package and 1-D or 2-D data matrix barcodes on the 
homogenous case {2013, sec. 582(a)(9)(A)(i-ii)}. 
The 1-D barcode can be the GS1-128 that incorporates the product identifier into 
the barcode along with serial number, batch/lot number, and expiration date. GS1-128 has a 
48 alphanumeric capacity that uses application identifiers (AI), uses unique GS1 identifiers, 
and is not omnidirectional. The following is an example of GS1-128 barcode that uses 
GTIN-14 with barcode values only (GS1, 2013c). (see Figure 48) 
(01) 1 0 6 1 4 1 4 1 0 0 7 3 4 6
AI GTIN
Figure 48     GS1-128 Barcode
Encoding a GTIN-14
Source: file:///N:/GS1 Rules/How to Build a 
GS1 GTIN into a GS1-128 for Produce 6.2.pdf
Retrieved: July 6, 2014
 
Next is an example of a GS1-128 barcode that includes the GTIN-14 and batch/log 





(01) 1 0 6 1 4 1 4 1 0 0 7 3 4 6 (10) 1 2 3 4 0 2 2 3 A B C
AI AIGTIN BATCH/LOT NUMBER
GTIN-14 and Batch/Lot Number
Figure 49     GS1-128 Barcode Encoding a
Source: file:///N:/GS1 Rules/How to Build a GS1 GTIN into a GS1-128 for Produce 6.2.pdf
Retrieved: July 6, 2014
 
The value of (01) and (10) are application identifiers with (01) GTIN and (10) being 
batch/lot number. Remember GTIN-14 is our product identifier.  
The 2-D data matrix barcode will be the GS1 DataMatrix (version ECC 200). GS1 
DataMatrix has the capacity of 3116 numeric or 2335 alphanumeric, carries application 
identifiers, has a unique GS1 identifier, and is scanned by a camera-based device only (GS1, 
2011). The following is an example of a GS1 Datamatrix. (see Figure 50) 
Figure 50     GS1 Datamatrix 2D Barcode
Source: http://www.intrex.pl/?lang=en&sec=applications&co=14
Retrieved: July 8, 2014
 
This example has stored the product identifier (01), batch number (10), expiration 
date (17), and the serial number (21). This serial number could be the serial number required 
for the SNI. However, we haven't discussed how to incorporate the FDA NDC into GS1 
standards. 
FDA NDC is comprised of a ten-digits code that has different formats: 4-4-2, 5-3-2, 
and 5-4-1 (FDA, 2012c). The first segment is the labeler code which identifies the labeler. 
The second segment is the product code which denotes specific strength, dosage form, and 





denotes package size and type. Package type can be package, box, carton, case, pouch, blister 
packs, or other containers listed in the NDC package table. 
The following is an excerpt from the FDA labeler table retrieved from the FDA 
website on May 21, 2014. (see Figure 51) 
Figure 51     NDC/NHRIC Labeler Codes
Source: http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm191017.htm




0002 Eli Lilly and Company
0003 E.R. Squibb & Sons, L.L.C.
0004 Genentech, Inc.
0005 Wyeth Pharmaceutical Division of Wyeth Holdings Corporation, a subsidiary of Pfizer Inc.
0006 Merck Sharp & Dohme Corp.
0007 GlaxoSmithKline LLC
0008 Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
0009 Pharmacia and Upjohn Company
0010 Boehringer Ingelheim Vetmedica, Inc.
 
These labeler codes can be incorporated into the company prefix provided by GS1 




Retrieved: July 7, 2014
GS1 Prefix 03
FDA NDC Labeler Code 0005
GS1 Company Prefix 030005
Figure 52   GS1 Company Prefix using Labeler Code
 
The GS1 company prefix would be 030005 for Wyeth Pharmaceutical Division. This 
would leave five digits to allow for any labeler to identifier up to 100,000 products/packages. 
These five digits would be used to store the five digits of the product/package number. The 





1 2 3 4 5 6 7 8 9 10 11 12 13 14
0 0 3 0 0 0 5 2 5 0 0 2 3 5
GTIN-14
Figure 53     GTIN-14 using 
Company Prefix and 
Package Code
 
This represents Wyeth's drug called Fibercon that consists of calcium polycarbophil, 
625 mg per tablet, and a package is 1 bottle of 140 tablets. To serialize this product, all you 
would have to do is to add the AI of 21 for serial number and you would have an SNI that 
could be represented by GS1-128 or 2-D DataMatrix. 
Since the FDA NDC is incorporated into the GTIN-14, then any change in the 
NDC would require a new GTIN-14 to be created. This means any change in the product 
code or package code of the NDC would require a new NDC and thus, a new GTIN-14. 
Whenever the package level changes, a new GTIN will be created for the new configuration. 
This would cover the repackager that might break down a box down to a case or consolidate 
several cases into a box. If the batch/lot number or expiration date changes, then a new 
GTIN-14 would have to be created. 
3.9.8 DSCSA Product Identifier Verification using GS1 GDSN 
Now that the implementation of the DSCSA product verification using GS1 GDSN 





























1. Load data: Manufacturer or Repackager registers product and company information to its data pool
2. Register data: a small subset of this data is sent to the GS1 Global Registry
3. Request subscription: Repackager, Wholesaler, Dispenser subscribes to receive Manufacturer or Repackager information
4. Publish data: Manufacturer or Repackager data pool publishes the requested information to the requester data pool
5. Confirm & Inform: Repackager, Wholesaler, Dispenser sends a confirmation to the Manufacturer or Repackager local 
data pool which informs them of the action taken by the sending party in using the information. 
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4. Discussion of the DSCSA Effectiveness 
4.1 Introduction 
This discussion will focus on the whether the DSCSA basic design can prevent 
counterfeit drugs from entering the USPSC. Using the previous discussed cases of 
counterfeit drugs entering the USPSC in section 2.5.3.5 of this thesis and some new ones, we 
discuss how DSCSA will affect those examples of counterfeit drugs entering the USPSC. 
The scope of the DSCSA only covers the USPSC and would not cover the counterfeit API 
coming from overseas. However, current FDA rules require that only FDA-approved 
businesses can make API for U.S. manufacturers. As was determined in the heparin case in 
section 2.5.3., it was at the tertiary level of suppliers where the counterfeit ingredients were 
introduced into the heparin API.  
DSCSA begins with definitions. DSCSA defines who are trading partners:  
manufacturer, wholesale distributor, repackagers, dispensers, and third party logistics 
providers. All these trading partners have to be authorized according DSCSA. To be 
authorized, they must be licensed by the state or by the FDA. In addition, the owner of a 
distributor must be without a felony conviction that relates to dubious behavior related to 
the USPSC. The rules of dealing with only authorized trading partners would prevent 
counterfeit drugs from entering the USPSC, such as the case of counterfeit Avastin which 
started somewhere in the middle east, to a warehouse company in Switzerland, to Germany 
and England, and then onto the United States wholesale distributors. The requirement of 
only dealing with authorized trading partners and owners without certain convictions makes 
the USPSC a closed system. However, as we will discuss in the next section, it doesn't stop 





party. The first stop on our discussion is with manufacturers that can introduce counterfeit 
drugs to the USPSC.  
4.2 Manufacturers 
In the 1990s Biochimica Opos, an Italian pharmaceutical company which was solely 
owned by the French pharmaceutical company Roussel-Uclaf, falsified records to conceal its 
use of unauthorized manufacturing plants in Italy, France, and Romania to produce the 
antibiotic cefaclor. Cefaclor was eventually recalled and Biochimica Opos withdrew its 
approved marketing applications (PEW Trusts, 2014). 
In 2001, Roussel-Uclaf pleaded guilty to felony charges of conspiracy and defrauding 
the FDA. Roussel-Uclaf was ordered to pay $33 million, $10 million in proceeds and $23 
million as a criminal fine, to the U.S. government. Roussel-Uclaf also pleaded guilty on a 
two-count indictment charge for selling an adulterated drug in the U.S. market in 1995 and 
1996 via Biochimica Opos. Roussel-Uclaf merged with  Hoechst in 1997 which later became 
Aventis Pharma AG by 2001 (PEW Trusts, 2014). 
Ranbaxy was FDA approved to manufacturer and import drugs into the United 
States. However, the Ranbaxy's manufacturing plants in India had been selling Guafenesin 
LA Tablets 600 mg extended release product in the U.S. without FDA approval in 2002. In 
2008, the Department of Justice subpoena motion claimed that Ranbaxy had used API from 
unapproved FDA sites. On February 25, 2009, the FDA prohibited Ranbaxy's APIs and 
finished products from three manufacturing plants from entering the U.S market. Ranbaxy 
failed to produce drugs within Good Manufacturing Standards and was found guilty of 
selling adulterated drugs in the U.S. in 2013, given a fine of $150 million and had to pay $350 
million in claims for a total of $500 million (Department of Justice, 2013). On September 16, 





prohibits its drug products from entering the U.S. market (FDA, 2014b). On January 23, 
2014, the FDA prohibited Ranbaxy's Toansa plant from manufacturing and distribution 
APIs for the U.S. market (FDA, 2014b). 
Although the above examples are worst case scenarios, every year the FDA issues 
warning letters for not following good manufacturing practices and adulteration of API and 
finished pharmaceutical goods in the U.S. and abroad. If the manufacturers of API and 
finished pharmaceutical products only deal with authorized trading partners, many of these 
severe problems of bad drugs will not occur. However, in the case of Ranbaxy, it is the 
culture of the company that has to change. 
4.3 Wholesale Distributors 
Unscrupulous wholesale distributors have made millions of dollars buying off the 
gray market and from secondary wholesalers that bought their drugs from non-FDA 
authorized companies. In 2000 and 2001, Dutchess Business Services, a drug wholesaler 
licensed in Nevada, and its successor, Legend Pharmaceuticals Inc., bought counterfeit 
Serostim and later sold it to McKesson Corp. which then sold it to retail pharmacies 
(Swafford, 2004). In addition, Dutchess and Legend were found guilty of doing business 
with Florida and South Carolina drug wholesale distributor companies that were not 
authorized to possess the drugs involved in the transactions (Hardesty, 2014; Swafford, 
2004). The person that sold the counterfeit drug, Serostim, to the Florida drug wholesale 
company, Crystal Coast, who sold it to Dutchess, had been operating a drug wholesale 
business without license in the state of Florida. Although Florida and Nevada have pedigree 
laws on the buying and selling of drugs in their states, Dutchess and Legend failed to get and 
properly maintain appropriate pedigree records from their sellers and provide adequate and 





Dutchess $1,000 for each of 399 counts and $250 for each of the remaining 483 counts for a 
total fine of $519,750 (Hardesty, 2014). Legend was assessed a fine of $250 for each of 125 
counts for a total of $31,250 (Hardesty, 2014). Needless to say, Dutchess and Legend lost 
their wholesale distributor licenses in Nevada. 
One of states that seemed to have a problem with wholesale distributors selling 
diverted and/or counterfeit drugs was Florida. Florida had a pedigree system that was 
required for secondary wholesalers but it wasn't enforced (Stovall, 2006). On July 21, 2003, 
nineteen people were indicted for selling counterfeit drugs (The New York Times, 2003). 
Eighteen were indicted for a variety of charges from racketeering, conspiracy, and other 
offenses in regards to prescription drug fraud. The other indictment was on the relabeling of 
Epogen that indicated a potency that was 20 times greater than its actual potency. 
 A grand jury was convened in 2003 thatand concluded that the Florida wholesale 
pharmaceutical industry had become corrupt due to criminal elements (Stovall, 2006). Some 
Florida drug wholesalers who had been given licenses to operate in Florida had one or more 
felony convictions (Hileman, 2003). In addition, many of those Florida drug wholesalers did 
not have the proper training or experience to handle, store, or deal in pharmaceuticals 
(Hileman, 2003). Additionally, according to the grand jury report, corrupt secondary 
wholesalers in Florida had done business with millions of dollars of prescription drugs that 
were later to be found counterfeit (Stovall, 2006). Counterfeiters used relabeling, dilution, 
substitution, and overstating the potency techniques when counterfeiting the drugs. 
In 2005, three businesses and eleven individuals were charged with a $42 million 
dollar conspiracy to distribute counterfeit and misbranded Lipitor smuggled into the United 





would have occurred without corrupt wholesale drug distributors that helped in the 
distribution of these drugs. This case caused the recall of 18 million Lipitor tablets.  
In 2012, there were two cases that resulted in over a billion dollars in fraud due to 
drug diversion that covered multiple states where 71 people and three corporations were 
charged (NABP, 2013). Drugs that were dispensed to Medicaid patients were diverted and 
resold back to corrupt wholesalers, who then sold the drugs to pharmacies. The drug 
diversion occurred from 2007 until 2011, and although fraudulent drug pedigrees were 
supplied, it was impossible for the chain and independent pharmacies to trace a pedigree to 
determine a place of origin (NABP, 2013). 
The current case of Avastin and Altuzan further indicts the wholesale distributor that 
is willing to cut corners to make a buck which in turn can cause loss of life. In most cases, 
dealing with only authorized trade partners will prevent the introduction of counterfeit drugs 
into the USPSC. In DSCSA, verification is not only with the seller but with the manufacturer 
or repackager. In a Nevada case of counterfeit drugs, it wasn't until the manufacturer was 
contacted before it was determined by the lot number that the drugs were counterfeit 
(Swafford, 2004). Furthermore, by contacting the manufacturer, a determination on whether 
the seller is authorized to sell the drug becomes known. The database of authorized 
wholesale distributors which is maintained by the FDA will help trading partners to 
determine authorized wholesale distributors. In many of these cases given, the main theme 
was that none of the incidences were found through inspections but through serendipitous 
means or after the fraud was committed and discovered. 
4.4 Pharmacy and Pharmacist 
Counterfeit, diverted, and diluted drugs do enter the USPSC via corrupt pharmacies 





without known provenance. Another crime that is investigated by the FDA OCI has to do 
with the pharmacy or pharmacist selling free samples that the pharmaceutical sales 
representative gives to the pharmacy or pharmacist to give to licensed physicians (FDA, 
2011). In this example, the pharmacist or pharmacy keeps the drug and sells it to their 
customer for a nice profit. When the pharmacy or pharmacist bills the insurance company or 
Medicare or Medicaid for the free samples, you can add health care reimbursement fraud to 
the indictment. 
There is a case of a licensed pharmacist buying counterfeit drugs, Cialis and Viagra, 
from China for his pharmacy in San Jacinto, Texas (FDA, 2011). His order was 1000 tablets 
of counterfeit Cialis and 4500 tablets of Viagra which cost him 30 cents per tablet for a total 
of $1650. At that time, the wholesale price per pill for Cialis was $9.55 and $13.55 for Viagra 
which would provide him with a net profit of $68,875. The special agents of Immigration 
and Customs Enforcement (ICE) and FDA OCI were involved with this purchase by posing 
as deliverymen. The licensed pharmacist was sentence to two years in federal prison without 
a chance of parole. 
In Kansas City, MO for ten years, 1992 to 2002, a pharmacist and owner of two 
pharmacies, Robert Courtney, diluted over 98,000 prescriptions written by 400 physicians 
(Belluck, 2001; Elliot, 2002). Some of the drugs that were diluted were anticancer drugs: 
Taxol and Gemzar. The rest is unknown as Robert Courtney’s spurious deeds were 
completed intermittently with no records kept. Lawsuits were filed against the 
pharmaceutical companies of Eli Lilly and Myers Squib which settled out of court for $72 
million (Potent Settlement for Drug Dilution Case.2003; M. Morris, 2013). 
DSCA clearly states that business must be completed between authorize trading 





history to the manufacturer, and product identifiers are to be verified with the manufacturer 
or repackager. If the pharmacy or pharmacist follow those rules, the drugs they sell will be 
good. However, it really doesn't cover personal criminal acts which are covered by federal 
and state laws. 
4.5 Physicians and Healthcare Providers 
Physicians and healthcare providers have been involved in distributing counterfeit, 
diverted, and diluted drugs. DSCSA doesn't regulate physicians and healthcare providers as 
they are regulated by the states. Because the physicians and healthcare providers are 
regulated by the states, each state or group of states needs to pass laws that would require 







Although many of the details of the DSCSA will be worked out in the next ten years, 
DSCSA basic structure and requirements should be adequate enough to reduce the 
probability of counterfeit drugs from entering the USPSC. The requirement of obtaining 
drugs only from FDA authorized trading partners will prevent counterfeit drugs from the 
gray market from entering the USPSC. Verification of the drugs received by the buyer 
through the manufacturer and repackager should identify potential counterfeit drugs at their 
point of origin into the USPSC. The requirement of transaction records that go back to the 
manufacturer before accepting the drug should further make it more difficult for counterfeit 
drugs to enteri the USPSC. Vigilance by the FDA will be very important in making sure the 
USPSC is secure. DSCSA doesn't mitigate the actions of the unscrupulous manufacturer, 
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